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Advancing knowledge in cancer treatment can only be achieved with the conduct of 
clinical trials.  Barriers to adult cancer clinical trial participation have been extensively 
examined, yet nearly 20% of trials fail due to low patient enrollment.  This dissertation considers 
the gaps in knowledge related to health policy, healthcare industry changes, and variation in 
oncology service provider behavior in the conduct of cancer clinical trials.   
In the first study, we used data collected from an internet-based survey of cancer clinical 
trial sites across the nation and found that sites continued to receive insurance coverage denials 
for patients seeking treatment through participation in a cancer clinical trial after the 2010 
Affordable Care Act’s mandate requiring most private health insurers to cover routine patient 
care costs for trial participation.  Organizational characteristics of being National Cancer 
Institute designated and having previous state legislation related to coverage for clinical trial 
participation were not associated with receiving denials, while being an academic medical center 
and using a precertification process were significantly associated with receiving insurance 
denials.  These results suggest that insurance denials and delays continue to be formidable 
barriers to the research community in achieving adequate and timely trial enrollment, thus 
negatively affecting the pace of cancer discovery. 
The second study used previously collected qualitative data and a validated theoretical 
framework to understand the substantial decrease in clinical trial enrollment related to changes in 
community cancer site personnel behavior after being acquired by a large, tertiary health system.  
These staff perceived many barriers to enrollment being present after the acquisition, particularly 
related to the opportunity and their capability to conduct clinical trials.  The lack of support to 
conduct clinical trials by having adequate staff and available trials within which to enroll were 
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perceived to be the primary barriers. Use of a theoretical model to understand changes in 
behavior adds to the empirically-based clinical trial enrollment barrier literature, and may be 
more helpful in matching future interventions to behavior determinants to address remaining 
barriers.  
There is demonstrated variation in providers following treatment guidelines.  The final 
study was a retrospective analysis of data from a large health system’s electronic health record 
and clinical trial management systems to assess radiation oncologist variation in the completion 
of a field for recording patient assessment for trial participation.  Completion of this field may 
serve as a proxy for radiation oncologist awareness of available clinical trials. We found 
radiation oncologist characteristics are not significantly correlated with recording patient 
assessment for clinical trial participation.  This field was completed just over 40% of the time, 
identifying the need for additional evaluation of the factors motivating radiation oncologists to 
complete this field. 
 Overall, there are organization and provider factors that negatively affect cancer research 
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Chapter I: Introduction  
Although it is estimated that over 1.7 million new cancer cases will be diagnosed and 
there will be nearly 610,000 deaths in the United States (US) throughout 2018, the overall cancer 
death rate has fallen by 25% over the last 25 years.1  Decreases in the overall death rate from 
cancer in the US have been attributed to a number of factors including more effective treatments, 
which are only available after rigorous evaluation through the conduct of clinical trials.  Clinical 
trials are required for identifying new, more effective therapies for disease prevention, treatment, 
and rehabilitation for many diseases.2  Lack of timely and adequate clinical trial enrollment 
limits generalizability of results, can result in trial cancellation, and increases the timeline for 
regulatory approval of new therapies,3-5 consequently delaying information needed to develop 
improvements in patient care. Low trial accrual also jeopardizes institutional accreditation from 
key credentialing bodies such as the American College of Surgeons6 and National Cancer 
Institute (NCI),7 potentially reducing patient access to the most innovative and specialized care 
from a team of cancer experts.   
The NCI is the world’s largest funder of cancer research with a 2019 fiscal year budget 
just over $5.6 billion,8 and throughout the past decade, had an average yearly enrollment to 
cancer clinical trials of over 20,000 patients.9  The Institute of Medicine’s 2010 assessment of 
the NCI’s clinical trial network found that nearly 40% of trials never completed10 and subsequent 
analysis of NCI funded trials reported similar findings.  Cheng et al. analyzed trials conducted 
from 2000-2004 and reported nearly forty percent (37.9%) of trials failed to achieve enrollment 
goals.11 Considering phase III trials from 2000-2007, Korn et al. estimated nearly a third (28%) 
of the trials were discontinued due to meeting less than 90% of the recruitment goal.12  
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The largest cost in the research and development of new treatments for biopharmaceutical 
companies is the conduct of clinical trials; billions of dollars are spent every year in this stage of 
development.13  A seven year evaluation of enrollment to adult cancer clinical trials reported to 
clinicaltrials.gov (the largest clinical trials database run by the National Institutes of Health), 
found a similar rate of the number of trials that failed to meet enrollment (39%), and industry 
sponsored trials were more likely than federally funded trials to not be completed.14  The cost of 
low enrolling trials to clinical trial sites is also significant.  One institution estimated the cost of 
uncompensated patient care for low enrolling trials to be $1 million a year, not including 
investigator time and effort, and a greater number of low-enrolling trials were government 
funded over industry-sponsored.15  
The significant investments wasted when trials fail to achieve enrollment goals are not 
solely related to the financing of conducting trials.  There are lost opportunity costs for those 
funds.  The funds are unable to be spent supporting more successful programs.  There are ethical 
challenges when patients willingly participate in clinical trials, yet their contribution is never 
realized.  Finally, the wait to get new treatments to those most in need is prolonged.  Gaining a 
better understanding of the barriers that contribute to low enrollment into adult cancer clinical 
trials is the first step in eliminating these barriers, with the goal to achieve greater trial 
completion. 
Researchers have long sought to explain low trial enrollment, but despite the barriers to 
enrollment having been extensively examined and reported in the literature,4,16-22 timely and 
adequate enrollment to clinical trials remains a challenge.  Researchers have identified barriers to 
clinical trial enrollment as specifically related to the organization, physician, and patient.21,23-25  
Patient-related factors are based upon an individual’s decision to participate in a trial and take 
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into account family, faith, and trust in the health care system,26 factors generally beyond the 
control of health care administrators.  Non-patient barriers, specifically those related to research 
organizations (clinical trial sites) and physicians, have the potential to be more actionable by 
cancer center leadership in mitigating enrollment barriers due to the likelihood of these barriers 
affecting all potential trial patients.  Organizations successful in achieving trial enrollment goals 
have infrastructure including adequate staff and research support,20 physician-level accrual 
expectations established by organizational leadership,24 and mechanisms in place to address the 
financial costs of conducting and participating clinical trials.27   
Conceptual Framework  
The process of enrolling a patient into a clinical trial is complex and is shaped by the 
engagement of the stakeholders at multiple levels, including interaction between the patient, 
physician and the broader environment in which care is being provided (the organization).  
Previous research evaluating adult cancer clinical trial enrollment identified the barriers to 
enrollment specifically related to the organization, physician and patient.21,23-25   
The framework by Ford et al. describes influences on recruitment and retention of 
patients by detailing three key factors:  Awareness, Opportunity and Acceptance (Appendix A).   
These researchers posit that in order for a patient to accept or refuse trial participation, they must 
first be aware of the trial, then have the opportunity to participate.28  The patient deciding to 
participate in and being eligible for a trial is the ideal outcome, however there are elements that 
must be in place to get to the point of the patient making this decision. 
Barriers to trial participation were grouped into structural, clinical and attitudinal 
categories by Unger et al. (Appendix B).   In this simplified flow diagram of the trial enrollment 
process, these researchers also recognized that there are sequential steps to be taken before a 
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patient could even consider participating in a trial.21 Many of these steps are related to 
organization and physician characteristics.  Additionally, this work identified the need to 
increase efforts to reduce these non-patient related barriers to facilitate increased clinical trial 
enrollment.21 
Each model effectively identifies the broad pillars describing barriers to enrollment, yet 
synergistically may offer a stronger framework for evaluating the complexity of trial enrollment 
within a larger context.  Therefore, adapting and combining the works of Ford28 and Unger,21 I 
developed a framework conceptualizing the trial enrollment process depicting these dynamic 
relationships, with a focus on organizations and providers, to identify key factors influencing 
trial enrollment (Figure 1).  
 
Figure 1 Conceptual Framework 
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Organizational characteristics include the location of the facility, the culture and 
personnel hierarchy (environment). The level of support for enrolling patients into clinical trials 
from the organization’s leadership such as establishing accrual expectations, offering trainings 
and giving incentives to enroll patients, has been shown to lead to increased enrollment.24   
Successful trial sites have adequate infrastructure (support) to conduct clinical trials, including 
dedicated research personnel such as coordinators and nurses (staff),20 an efficient research 
approval process,29 and mechanisms in place to address the financial costs of conducting and 
participating in clinical trials.27 With the necessary organizational support in place, the next 
crucial factor in successful trial enrollment is the physician. 
Physicians have the most significant impact on trial enrollment, and it is often an 
oncologist’s failure to offer a trial that substantially contributes to low accrual.30-32  A 
physician’s lack of awareness of available trials has been cited as one of the main reasons for 
low enrollment.4,33-35  A physician’s knowledge of the clinical trial process, and more specifically 
a trial’s design (i.e., inclusion/exclusion criteria and treatment groups) also affect patient clinical 
trial enrollment.36,37  Further, a physician’s attitudes and beliefs about the scientific value, 
appropriate treatment course for the patient, and a patient’s ability to complete the trial protocol 
requirements, all directly affect whether participation in a trial is even discussed.38,39  There are 
tools and interventions that can be used by physicians as decision aids when choosing a 
treatment path with their patients, but it is unknown to what degree tools are used and what 
physician characteristics are associated with their use. 
Failing to offer a trial may be a result of a lack of physician awareness of available trials, 
a misunderstanding of the purpose of clinical trials, or limits on sufficient resources to 
thoroughly discuss trial participation with the patient (structural barriers).40  Most of the 
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frameworks used for evaluating barriers to cancer clinical trial enrollment have come from 
empirical findings and may be incomplete.  These frameworks have been used for assessing 
policy, organizations, providers, and patients.  Using a comprehensive theoretical framework to 
investigate factors affecting enrollment has been suggested as a method for further exploring 
enrollment barriers41 and may be more helpful in matching future interventions to determinants.  
The Theoretical Domains Framework (TDF), is an integrative framework that synthesizes 
128 theoretical constructs drawn from 33 theories into 14 domains relevant to implementation 
behavior.42 The TDF was specifically developed to identify determinants of healthcare 
professional behavior,42 allowing for targeted change intervention.  In 2012, the framework was 
further refined and validated, and includes the COM-B43 (Appendix C). The developers of the 
COM-B framework suggest that an individual’s behavior (B) is shaped by three essential 
conditions: Capability (C), Opportunity (O), and Motivation (M), collectively referred to as 
COM-B.44  Capability refers to individual's psychological and physical capacity to engage in 
intended activities. Opportunity is defined as factors external to the individual that prompt or 
make behavior possible. Motivation is defined as internal psychological processes that energize 
and direct behavior. This framework allows for structured exploration of potential facilitators 
and barriers to trial enrollment. 
Structure 
This dissertation follows a three-essay format and explores the gaps in knowledge related 
to organization and oncologist characteristics influencing the conduct of cancer clinical trials.   
Particularly, I examine the characteristics of cancer research sites experiencing denials for health 
insurance coverage of adult cancer patients seeking treatment through participation in a clinical 
trial following the passing of national policy aimed at eliminating clinical trial insurance denials.  
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Next, the role of organizational transition in mediating the conduct of clinical trials is evaluated 
using a validated theoretical framework to understand a substantial decrease in clinical trial 
enrollment at sites previously recognized as high enrollers.  Finally, I evaluate the variation in 
oncologist’s use of an embedded field within an electronic health record for recording patient 
assessment for participation in a clinical trial. 
The first essay in this dissertation assesses organizational characteristics associated with 
receiving insurance denials for cancer patients seeking treatment through participation in a 
clinical trial after the Affordable Care Act (ACA) clinical trials mandate using nationally survey 
data collected from research sites conducting cancer clinical trials.  The ACA significantly 
increased the number of Americans with health insurance, and was the first national mandate to 
require most private health plans and insurers to provide coverage of routine patient care costs 
for items and services furnished in connection with participation in a clinical trial.45  Many 
assumed that national policies would alleviate this enrollment barrier, since insurance denial of 
routine care costs for trial participation and the length of time to receive a response from the 
insurer about coverage, have both been identified as formidable barriers to adult cancer clinical 
trial enrollment.3-5,27,46-50  It was unknown whether comprehensive legislation would eliminate 
this barrier, and subsequently increase enrollment, especially since prior research on the 
effectiveness of state and federal policies enacted prior to the ACA and aimed at eliminating the 
insurance denial barrier yielded variable results regarding the impact of these policies on cancer 
clinical trial participation.3,5,18,51-54  Through this work, we sought to investigate the impact of the 
ACA clinical trial mandate on cancer centers, and to identify organizational characteristics that 
may be associated with receiving insurer denials. 
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Another strategy cancer centers use to increase clinical trial accrual is structural. Cancer 
centers can merge with or acquire high performing sites, to expand their clinical trial offerings.  
However, the degree to which these strategies are effective is unknown and unintended 
consequences of these approaches have not been assessed. Therefore, the second essay examines 
the experiences of community-based oncology clinic personnel to explain the significant drop in 
accrual to adult cancer clinical trials after acquisition by a large, tertiary academic medical 
center.  Data from this original research included observations of each practice, conducting focus 
groups, and performing semi-structured interviews.  These data are analyzed using the TDF to 
identify key organizational and provider barriers and facilitators that influence trial enrollment.  
This assessment follows the model to examine the overlap of organization and physician 
characteristics.  The results provide evidence that the change in organizational structure 
significantly impacted the community sites’ opportunity to enroll patients, providing insights into 
the 70% decline in clinical trial enrollment that occurred around the time of the acquisition.    
Using an Electronic Health Record (EHR) has been shown to increase clinical trial 
participation.55  As a strategy to address limited memory and attention related to following 
guidelines, the use of a prompt within the EHR for documenting assessment of patients being 
evaluated for palliative care substantially increased adherence to guidelines.56   The utility of an 
similarly embedded field within an EHR for recording patient assessment for possible trial 
participation has not been assessed.  My final essay uses secondary data analysis to evaluate the 
completion of this field by all radiation oncologists across one major health system.  Radiation 
oncologists were studied because they see all types of cancer patients, were located across this 
health system’s many clinics, and play an important role in trial recruitment and conduct.38,39 
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 Specific physician characteristics such as gender, time in practice, practice type, and 
patient volume have been found to be associated with treatment decisions and trial 
enrollment,57,58 and are used to understand the variation in provider completion of this embedded 
field.   From February 2017 to January 2018, data extracted from both the EHR and clinical trial 
management system (which captures data from patients considering or enrolled into a clinical 
trial), are used to evaluate radiation oncologist characteristics to predict completion of the 
embedded field for recording patient clinical trial assessment.  Then, assessment of the 
congruency between the recorded response and the patient’s actual trial status are compared.  
The aims of this study are to identify key characteristics of radiation oncologists related to 
completion of the patient assessment for trial participation field in the electronic health record, 
and to estimate the level of congruency between the recorded assessment and the patient’s actual 
trial status.  
Statement of Purpose  
  The purpose of this multi-method study is to gain a better understanding of organizational 
and provider characteristics that influence enrollment to adult cancer clinical trials within the 
umbrella of opportunity and awareness. The dissertation contributes to the literature in three key 
ways.  This work provides new evidence regarding cancer research center characteristics and 
experiences with receiving insurance denials for patients considering trial participation following 
enactment of the ACA’s mandate for most insurers to cover cancer clinical trial participation.  
Next, this work is the first to analyze the motivation of the apparent behavior changes of 
personnel resulting in a decline in trial enrollment after acquisition by a larger entity using a 
validated behavior change framework.  Finally, the use of an embedded field within an electronic 
health record by providers, specifically radiation oncologists, for recording patient assessment 
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for trial participation has a strong potential for large-scale, low-cost implementation across 
institutions that use electronic health records.  This last essay contributes early evidence of 




Chapter II: Insurance Denials for Cancer Clinical Trial Participation After 
the Affordable Care Act Mandate 
 
Sections of this chapter are reprinted with permission from Mackay, C.B., Antonelli, K.R., 
Bruinooge, S.S., Saint Onge, J., Ellis, S.D. (2017) Insurance Denials for Cancer Clinical Trial 
Participation After the Affordable Care Act Mandate. Cancer 123, 2893-2900. The sections 
contributed by C.B. Mackay are presented in this chapter in full alongside new, never-before 
published results. 
Introduction 
The Affordable Care Act (ACA) has not only significantly increased the number of 
Americans with health insurance, but was also the first national mandate to require most private 
health plans and insurers to provide coverage of routine patient care costs for items and services 
furnished in connection with participation in a clinical trial.45  This component of the legislation 
is important because insurance denial of routine care costs for trial participation and the length of 
time to receive a response from the insurer about coverage, have both been identified as 
formidable barriers to adult cancer clinical trial enrollment.3-5,27,46-50  An examination of this self-
implementing60 statute has yet to be reported.  Research on the effectiveness of state and federal 
policies enacted prior to the ACA and aimed at eliminating the insurance denial barrier, yielded 
variable results regarding the impact on cancer clinical trial participation.3,5,18,51-54   
Prior to the ACA, federal regulations required trial coverage for Medicare beneficiaries.  
State statutes were in place to cover patients under other plans, but varied in the types of trials, 
beneficiaries, and payors affected, creating inconsistency in coverage. For example, Medicaid 
coverage rules are set by each state and not every state requires trial coverage for Medicaid 




Grandfathered plans are insurance plans that existed on or before the date of ACA 
implementation (March 23, 2010) that have not made significant coverage changes since that 
date. These plans are not required to meet the ACA’s clinical trial provision as long as they 
maintain their pre-ACA set of benefits.62  Health insurance plans federally regulated under the 
Employee Retirement Income Security Act of 1974 (ERISA) can qualify as grandfathered health 
plans, and be exempt from the coverage requirement.63  The degree to which these exempt plans 
affect trial participation is unknown.64  The current national initiative to accelerate cancer 
research to “end cancer as we know it” by doubling the pace of cancer research over the next five 
years,65 will likely involve conducting more clinical trials and enrolling more patients in trials. 
The success of this “Cancer Moonshot”0F1 may be impacted if insurance denials and delays for 
trial participation continue.  
The goal of this study was to assess early implementation of the ACA clinical trials 
mandate for cancer patients.  Specifically, we aimed to understand if insurance denials persist, 
and if so, to evaluate the reasons insurers used to justify denying coverage, as well as to identify 
specific research site characteristics associated with denials.   
Method 
Study Sample 
We surveyed diverse organizations conducting cancer clinical trials in 2015 regarding 
their experience with insurance coverage denials throughout the 2014 calendar year; the first 
year of the ACA trial mandate.  The sampling frame consisted of academic- and community-
based research sites conducting cancer clinical trials and affiliated with the American 
                                                 
1 In 2016, the National Cancer Moonshot Initiative was launched to increase efforts aimed at the prevention, 
diagnosis, and treatment of cancer by achieving a decade’s worth of progress in five years. 
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Association of Cancer Institutes-Clinical Research Initiative (AACI-CRI), American Society of 
Clinical Oncology- Research Community Forum, Midwest Cancer Alliance, and the Oncology 
Nursing Society-Clinical Trials Nurses Special Interest Group.  Approximately 550 non-
duplicate, distinct research sites were represented by these four organizational membership lists 
in the initial survey, with a subset of these sites represented in the focused survey.  Survey 
participants were incentivized with opportunities to receive a tablet computer and gift cards. The 
institutional review board at the University of Kansas-Lawrence exempted this study from 
human subjects review. 
Survey Design 
The survey questions were drafted using an iterative design process, with review by 
content experts.  The survey asked participants to report on interventional treatment trials to 
narrow the scope of the project to include only cancer treatment (versus prevention or detection) 
trials.  Pre-testing of the survey questions was performed with four representatives from the 
sampling frame.  Based upon feedback and a review of the data, the survey was divided into two 
instruments using multiple choice and open-ended responses to improve clarity.  Survey 
administration followed the recommendations of Dillman et al.66 for internet-based surveys and 
both surveys were administered through SurveyMonkey®.67 
Data Collection 
Initial survey 
To rapidly ascertain if insurance denials continued after ACA’s directive, effective 
January 1, 2014, the initial survey (Appendix D) was launched on April 6, 2015, capturing 
responses over a five-week period.  Emails with the survey link were sent by the respective 
organizations to 1,412 individuals associated with at least one of the participating organizations. 
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The initial five-question survey asked respondents to report experience with receiving denials 
from insurance companies for patients seeking trial participation along with basic site 
characteristics. Respondents were also asked to identify an organizational representative who 
could provide more thorough information about their oncology clinical trials program, including 
the process for determining insurance coverage for potential trial participants.  This brief 
questionnaire provided a timely, broad assessment of the status of clinical trial insurance denials.   
Focused survey 
The follow-up focused survey (Appendix E) was conducted May-July 2015 and was sent 
to key informants identified from the initial survey, as well as interested individuals identified 
during the July 2015 AACI-CRI meeting. This survey included 31 items pertaining to additional 
detailed experiences with insurers related to coverage for trial participation as well as a more 
comprehensive set of organizational characteristics.   
Measures 
 The main outcome variable was responses from insurers to cover routine care costs for 
trial participation (no/yes).  Having confirmed that sites were experiencing denials, we sought to 
identify research site characteristics associated with denials and to evaluate the reasons sites 
recorded as the insurers’ explanations for denying coverage. We collected the reasons sites were 
given from the insurers for denying coverage (non-mutually exclusive categories).  Delays in the 
initiation of treatment for cancer are known to significantly affect morbidity and mortality,68,69 
thus we evaluated the number of days to receive the insurer’s response regarding trial coverage.   
Site characteristics included type of organization (academic or community), any National 
Cancer Institute (NCI) designation, annual clinical trial enrollment, and use of a precertification 
process, all coded as (no/yes).  Precertification refers to obtaining approval from a patient’s 
15 
 
insurer or health plan before ordering certain tests or administering treatments, to confirm 
insurance payment and to inform the patient of any healthcare costs for which the patient may be 
responsible.  Nearly forty states and the District of Columbia enacted laws or cooperative 
agreements requiring insurers to cover routine care costs of cancer clinical trials prior to the 
ACA, thus a variable to control for previously existing state laws was included.     
To minimize bias, duplicate entries from the same institution were deleted after being 
evaluated by two of the researchers, using an algorithm to identify identical responses by 
institutional name, city, and zip code.  If the institution’s name was identical but the city was 
different, both entries were retained to reflect multiple locations.  If the name and city were 
identical, the entry reporting the highest enrollment was kept, with the expectation that with 
higher enrollment, sites would have greater experience interacting with insurers. Surveys 
returned with missing responses for the variables under evaluation were excluded from analysis.   
Statistical Analysis 
We summarized the reported experiences with insurance denials by number and percent 
response. Univariate statistical analysis was used to assess whether receiving an insurance denial 
occurred with use of a precertification process and separately with the presence of previous trial 
coverage legislation.  Multivariable logistic regression was used to measure the relationship 
between experiencing denials and performing precertification, controlling for the number of 
enrollments and presence of previous state law.  We used additional univariate analysis to 
evaluate potential associations between the variables in the focused survey.  Relationships 
between variables were considered statistically significant at the p<0.05 level. Analyses were 






The initial survey sample included 1,412 individuals, which yielded 309 responses (22% 
response rate).  Following the a priori algorithm, we excluded 57 responses (46 duplicates and 
11 incomplete), analyzing 252 unique site responses.  Respondents represented 48 states and the 
District of Columbia.  Most respondents (n=158; 62.7%), reported experiencing at least one 
insurance denial at their site during calendar year 2014.  Sites with coverage legislation prior to 
the ACA experienced similar rates of denials as states without (82.3% vs. 85.1%, χ2=50.7, 
p<0.001).  Sites performing precertification were more likely than those not performing 
precertification to report experiencing denials (69.3% vs. 41.7%, χ2=14.9, p<0.001).  After 
controlling for institution type, presence of state laws, and enrollment volume, sites using a 
precertification process were still significantly more likely to experience denials than sites 
without a precertification process (OR 3.04, 95% CI 1.55-5.99).   
Research Site Characteristics 
Among the 204 academic and community-based sites identified for the detailed 
assessment, 97 responses were received, representing 33 states with a response rate of 48%.  
After removing incomplete entries, 77 responses from unique sites were analyzed. 
Characteristics of research sites by insurance denial experience during the 2014 calendar year are 
listed in Table 1.  In this smaller subset analysis, although academic medical centers reported 
experiencing a denial more often than community sites (71.4% vs. 46.4%) and sites using a 
precertification process were more likely to report denials than sites without a process (58.7% vs. 
41.3%), neither relationship showed statistical significance. None of the site characteristics 
evaluated showed statistical significance.  
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Table 1 Research-Site Characteristics by Insurance-Denial Experience 




denials                 
n (%) 
Sites reporting 
insurance denials        




Medical Center 6 (28.6) 15 (71.4) 0.073 




Physician 10 (59) 7 (41) 
0.051 Hospital 20 (52.6) 18 (47.3) University 2 (14.3) 12 (85.7) 
















No 10 (71.4) 4 (28.6) 0.073 Yes 26 (41.3) 37 (58.7) 




No 6 (66.7) 3 (33.3) 0.291 
Yes 30 (44.1) 38 (55.9) 
Note: p-values calculated with Fisher’s exact test. 
Reported Insurer responses 
The survey allowed sites to report multiple reasons for insurance denials as shown in 
Figure 2.  Of the sites experiencing denials (n=41), most (n=33; 80.5%) reported being informed 
that the patient’s plan did not cover trial participation.  Over one-third of the sites reported that 
the plan was grandfathered under the ACA and therefore not required to cover clinical trials 
(n=16; 39.0%).  A similar number of sites (n=14; 34.2%) reported having a Medicare Advantage 
plan as a denial reason.  Statistically significant reasons (Figure 2, striped bar) for denials at 
academic compared to community sites included mention of the trial phase not being covered 
(p=0.038), without the specific phase identified, and the research site being excluded from the 
plan’s provider network (p=0.009).  Other reported reasons for denials included having a 
Medicaid plan; tests and medications not considered standard of care by the insurer; and having 
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international health insurance.   Only 20.8% (n=16) of the sites, reported receiving a decision 
from the insurer within 3 days of the initial request (Figure 3).   
 
   
Figure 2 Reasons Reported for Insurance Denials  
Note: Striped bars indicate statistical significance by Fisher’s exact test for academic versus community sites. 




























Figure 3 Time From Initial Insurer Ask for Trial Coverage to Insurer Decision 
Discussion 
Participation in clinical trials as part of cancer treatment is recommended by many 
medical and scientific professional organizations,71-73 and insurance denial for participation has 
been identified as an enrollment barrier.2-4,23,47,49,52,53  This study was conducted in 2015 to 
identify persistent challenges of the ACA trial mandate within its first year.  The results of this 
national survey drawing from a wide pool of academic and community-based research programs 
presents evidence that denials continued after the enactment of the ACA.   
Sites reported several reasons insurers provided to justify coverage denial (Figure 2). The 
most frequent denial reason sites reported receiving was that the insurer claimed the plan did not 
cover trial participation (n=33). The site being out of the insurers’ provider network (n=16) and 



























finding is consistent with the case study reported by Jain et al. of grandfathered plans remaining 
a barrier to enrollment.49  A 2015 Kaiser Family Foundation survey reported an average of 25% 
of covered workers are enrolled in grandfathered plans, with the percentage as high as 42% for 
individuals employed in firms with 25-49 employees.74  This suggests that a significant segment 
of the population may be without trial coverage.   
Plans are expected to lose grandfathered status over time.  Currently, there is no publicly 
available list of grandfathered plans. Therefore, to assess whether a plan is truly exempt from 
this mandate, research centers must take additional steps to confirm an insurer’s grandfathered 
status.  While this step may cause added burden, it may ultimately result in affirming trial 
coverage. 
The fourth reason reported for denials was due to patient’s participation in a Medicare 
Advantage (MA) plan (n=14). These patients are protected under the clinical trials policy 
national coverage determination (NCD) issued by the Centers for Medicare & Medicaid Services 
(CMS) in 200075,76 through traditional Medicare.  The MA plan is only required to compensate 
the enrollee for the difference in out-of-pocket costs between traditional Medicare and their MA 
plan.77  As such, MA plans routinely issue coverage denials because they are not required to 
cover clinical trials, but often do not clarify that the MA enrollee still has coverage under 
traditional Medicare.  If MA enrollees and providers do not understand that they have protections 
under traditional Medicare and the MA plan does not provide information, MA participants may 
be left out of trial participation entirely.  
A few sites reported that potential participants were excluded from trials due to Medicaid 
denials (n=4), which may be an appropriate exclusion. The ACA clinical trial mandate does not 
apply to Medicaid plans, and federal Medicaid requirements do not include clinical trial 
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coverage. Therefore, it is left to the individual states to determine Medicaid clinical trial 
coverage benefits.78 Although ten states and the District of Columbia have rules that ensure 
coverage to Medicaid beneficiaries,61 the majority of states do not have language that clearly 
requires coverage, so Medicaid beneficiaries may not be able to participate due to the lack of 
coverage.  Generalizability of clinical trial results is often scrutinized due to the 
underrepresentation of certain subgroups of the overall cancer population, including racial and 
ethnic minorities and the elderly.  Removing the insurance barrier to Medicaid beneficiaries may 
help make trial participants more representative of all cancer patients.  
Academic sites were more likely to indicate a denial due to phase of the trial and the site 
being excluded from the plan’s network.  Historically, early phase (especially phase I) clinical 
trials have been conducted by academic sites more often than community sites.  This is due to the 
ability of academic sites to provide infrastructure to support the increased demands of early 
phase trial conduct, including increased personnel, specialized equipment and adequate treatment 
space.79  In addition, changes in the healthcare environment have resulted in increasingly narrow 
networks, where many insurance plans limit the providers and sites available to enrollees, with 
the narrowest networks typically excluding academic centers.80  
There may be two possible explanations for the association between conducting 
precertification and experiencing denials.  First, because claims forms may not indicate services 
were performed within the context of a trial, insurers may not be aware that a patient is enrolled 
in a clinical trial if a site does not conduct precertification. Although the Medicare program has 
had a clinical trials policy in place since 2000, mandatory reporting of the clinical trial number 
and specification of routine care and research-related procedures was not mandatory until 
January 2014.81   
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Alternatively, the precertification process itself may be engendering higher levels of 
scrutiny from the insurers than what might otherwise be provided. When alerted to a clinical 
trial, insurers may employ greater scrutiny of individual coverage elements, in addition to 
determining whether the specific policy provides coverage.  There was not a statistically 
significant association in the use of a precertification by type of research site, and in fact, more 
of the community sites (89.8%) than academic (76.5%) centers reported using a precertification 
process.   
Since this survey was conducted, the Departments of Labor, Health and Human Services 
and the Treasury issued a document dated April 20, 2016, to provide some clarification to the 
ACA clinical trial policy.82  While beneficial, the document does not fully address the amount or 
type of documentation that insurers can require to approve trial participation, nor does it limit the 
duration of time to render a determination of coverage. Consequently, implementation ambiguity 
may remain, leaving patients and their providers seeking alternate treatment options due to 
treatment initiation delays.  
The lack of insurer’s timely response regarding trial coverage may have profound effects 
on the patient.  Aside from the anxiety of a cancer diagnosis or disease progression, the patient 
may be required to remain in the geographic area of where the planned treatment is to take place, 
which could mean a lengthier hospital or hotel stay.  In some cases, such as acute leukemias, the 
need for treatment is immediate, so the possibility of being treated on trial must be abandoned 
and an alternate therapy considered.  A shortened, standard review time for approval, if required 




Delays and denials from insurance companies related to clinical trials coverage prolong 
and further complicate the process of enrolling patients into clinical trials.  Described as a 
structural barrier to trial participation within the framework recently presented by Unger et al.,21 
lack of insurance coverage, either real or perceived, can deter both patients and providers from 
considering a trial.  Although just one step in the complex enrollment process, it is conceivable 
that by simply removing the uncertainty of trial coverage for everyone, patients, providers, and 
the drug development community at large, could focus on addressing the more complicated 
barriers affecting trial enrollment.  With fewer obstacles to overcome, the number of trials that 
fail to complete or are suspended due to slow or inadequate enrollment will decrease, and 
knowledge of safe and effective therapies will grow. Ultimately, patients will benefit, and 
providers and payers will have evidence to recommend and cover new therapies.  
Cancer centers must have effective and timely communication with the insurers to 
confirm patients have trial participation coverage and establish a process that allows immediate 
escalation when coverage is declined.  However, they must also engage insurers in addressing 
this problem, as it cannot be solved by cancer centers alone.  Our study asked cancer centers to 
describe the reasons insurers reported for denying trial coverage, but did not query insurers 
directly.  It is presumed that insurers issue coverage denials due to perceived increased costs, 
despite evidence indicating the incremental cost of treatment on trial versus off trial is 
negligible83-85 and the potential short-term savings from not paying for trial patients’ 
investigational therapies.  However, little research has been conducted on insurers’ motivations.   
The degree to which denials are intentional or the result of outmoded operations 
inconsistent with policy are not known. Intervention strategies with insurers may be more 
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effectively broached if potential miscommunications identified here were the focus of initial 
efforts: working with Medicare Advantage providers to clarify trial coverage policies, and 
publicly reporting plans’ grandfathered status. Long-term strategies might enable insurers to 
consider the return on their investment in clinical trials as opportunities to replace therapies of 
inferior value with more effective therapies that may reduce treatment intensity with fewer 
adverse effects. These efforts could be balanced by continued education to increase awareness 
among plan purchasers and their beneficiaries of the value of supporting the Cancer Moonshot 
through trial coverage. 
Limitations 
Several factors should be considered when reviewing these results.  First, survey 
respondents may not reflect the experiences of all research organizations.  Birken et al. 
emphasized “the need for a comprehensive list of programs that provide cancer treatment as a 
resource for researchers who study cancer programs.”86 Without an exhaustive sampling frame 
that includes all organizations/providers conducting cancer clinical trials, it is difficult to know 
how reflective respondents are of all research sites.  We addressed this by partnering with a 
variety of professional organizations active in cancer clinical research at diverse research sites. 
Second, there may be other research site characteristics that are associated with clinical trial 
participation that we were unable to measure, such as patient characteristics, provider attitudes 
towards clinical trials, and trial complexities.24,50,87,88     
Conclusion 
This is the first empirical evaluation of the ACA clinical trial mandate.  Our results 
showed persistence of insurance denials for routine costs associated with clinical trial despite this 
statutory requirement.  In our sample, there was a statistically significant difference between 
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reported denials from academic centers versus community sites, with numerous denial reasons 
reported.  Taken collectively, we consider the results of this study to demonstrate that insurance 
denials and delays continue to be formidable barriers to both the research and clinical 
communities in achieving adequate and timely trial enrollment, thus negatively affecting the 
pace of cancer research.  There remains the need for further promotion of insurance coverage and 
evaluation of the challenges to implementation of this ACA requirement to inform future action 
to eliminate this enrollment barrier.  
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Chapter III: Declines in Adult Cancer Clinical Trial Enrollment at 
Community Sites Surrounding Acquisition by a Tertiary Healthcare System: 
A Qualitative Study Applying the Integrated Theoretical Domains and 
Capability-Opportunity-Motivation Behavior Frameworks 
 
Introduction 
  Advances in the treatment of cancer have been achieved through successful completion 
of clinical trials.2  National treatment guidelines for cancer recommend consideration of clinical 
trials as part of the standard of care treatment.71  Despite strong endorsement and proven 
contributions of clinical trials, only 8% of cancer patients participate in trials, delaying 
information needed to develop improvements in patient care.89  
  Physicians have the most significant impact on trial enrollment,38,39 and it is often an 
oncologist’s failure to offer a trial contributing to low accrual.30-32   Physicians failing to offer a 
trial may be a result of being unaware of available trials, misunderstanding the purpose of 
clinical trials, or not having sufficient resources (e.g., limited staffing or limited patient contact 
time) to thoroughly discuss trial participation with the patient.40  The reasons for not offering 
participation in a clinical trial to patients as a treatment option vary and are significantly 
influenced by the support the oncologist receives from the organization’s leadership. Factors 
such as establishing accrual expectations, offering training, and giving incentives to enroll 
patients encourage oncologists to offer clinical trials.24  Much of the previous research utilized 
empirical data to identify clinical trial enrollment barriers, so less is known about the factors 
associated with research site personnel behavior related to declining trial enrollment.  Using a 
comprehensive theoretical framework to investigate factors affecting enrollment has been 
suggested as a method for further exploring enrollment barriers.41 
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  In 2011, one group of community oncology practice sites associated with a nationwide 
cancer research network were acquired by a large tertiary healthcare system.  Community cancer 
centers provide the majority of treatment to cancer patients, both as standard of care treatments 
and experimental treatments through participation in clinical trials.90  The announcement of the 
merger was in March 2011,91 with the completion of the acquisition announced in June 2011.92 
Public awareness of discussions regarding this particular acquisition is mostly lacking.  However 
collaborations between these organizations began in 2007 with the combination of the blood and 
marrow transplant programs.92   
  According to investment literature, acquisitions of healthcare companies can be 
completed as quickly as three months, but have also taken years.93,94  These deals, which 
encompass mergers, consolidations, and acquisitions are occurring more frequently.  Since the 
last quarter of 2014, over 200 healthcare deals per quarter have been announced each quarter.95  
Reasons for these business deals are not always apparent.  Typically with an acquisition, the 
acquired site(s) receive increased access to capital and other resources, while the acquiring site 
gains a greater market share.96  According to traditional investment literature, if organizations 
were providing similar services prior to a merger and the goal was to continue providing those 
services, there should be increased opportunity for patients to receive services after the merger.  
However, in the case of this acquisition, the opposite occurred. 
  The objective of this study was to explore the reasons for this decline, and understand the 
‘why’ and ‘how’ behind the enrollment decline experienced by the community cancer site 
personnel after acquisition. We undertook a qualitative case study approach to achieve this 
goal.97  In the years prior to the acquisition by the aforementioned health system, the community-
based cancer center sites that were acquired consistently ranked amongst the top ten in clinical 
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trial patient enrollment across the national network with which they were affiliated.  Clinical trial 
enrollment data from these sites prior to, and after the acquisition demonstrated a 70% drop in 
enrollment. 
  Integrating qualitative and quantitative data after analysis can maximize the strengths of 
each technique while minimizing weaknesses.  However this task can be difficult and should 
follow a framework.98  Therefore, the theoretical framework underpinning this analysis was the 
Theoretical Domains Framework (TDF)99 integrated with the Capability, Opportunity, and 
Motivation behavior (COM-B) framework.44 Using this theoretical framework fills an identified 
gap in theory-based analysis of cancer clinical trial enrollment barriers. 
Theoretical Framework 
  The TDF, is an integrative framework that synthesizes 128 theoretical constructs drawn 
from 33 theories into 14 domains relevant to implementation behavior.42 The TDF was 
specifically developed to identify determinants of healthcare professional behavior,42 allowing 
for targeted change intervention.  In 2012, Cane et al. further refined and validated the TDF, and 
included the  COM-B43 (Appendix C). The developers of the COM-B framework suggest that an 
individual’s behavior is shaped by three essential conditions: Capability (C), Opportunity (O), 
and Motivation (M), collectively referred to as COM-B.44  Capability refers to individual's 
psychological and physical capacity to engage in intended activities. Opportunity is defined as 
factors external to the individual that prompt or make behavior possible. Motivation is defined as 
internal psychological processes that energize and direct behavior. This framework allows for 





  My purpose in using the TDF with COM-B was to bring a theoretical perspective for 
understanding cancer clinical trial enrollment barriers, since previous work in this area has been 
based solely in empirical work.  I theorized the decrease in clinical trial enrollment at the 
community-based cancer sites was related to organization level changes resulting in site 
personnel behaviors and could best be explained according to the TDF domains of 
Environmental Context and Resources, Social Influences and Social/Professional Role and 
Identity. These three domains fall under the “Opportunity and Motivation” sources of behavior, 
assuming behaviors within “Capability” did not change due to the acquisition. Using a 
theoretical perspective may be more helpful in matching future interventions to behavior 
determinants to further address remaining barriers to trial enrollment.   
Method 
Organizations 
As part of the quest to become NCI-designated, a large tertiary medical center acquired a 
network of community-based cancer clinics.  The large medical center included a hospital, 
university campus, and an oncology care clinic.  Through these different locations, this 
institution offered routine patient care services, and conducted clinical trials.   
The community based-cancer clinics were privately-owned cancer clinics located across 
the same metropolitan area as the medical center.  There were thirteen locations offering patient 
care services, however only five of the clinics conducted cancer clinical trials. These five clinics 
were part of a national clinical trial network.  
Participants     
At the time these community cancer sites were acquired by a large tertiary medical 
center, the  five community cancer centers were conducting 73 clinical trials.92 These community 
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clinic site personnel numbered approximately 150, including front desk clerks, treatment and 
triage nurses, patient schedulers, managers, research staff, physicians, nurse practitioners, 
schedulers, laboratory, and pharmacy personnel. There were 15 individuals working at the 
smallest clinic (this clinic did not offer all treatment services, but did conduct clinical trials), 
while the larger clinics employed from 34 to 65 employees.   
  We sampled from the population of personnel working at each of these five community 
clinics from September 2014 through March 2015, approximately four years after the 
acquisition.  We used purposive sampling100 to recruit physicians, nurse practitioners, research 
staff and other key individuals from these community sites for this study. These staff remained at 
the community sites after the acquisition and were likely individuals with knowledge and 
experience related to prior patient recruitment practices and clinical trial conduct.   
Human Subjects 
Participation was voluntary and each participant was given a copy of the Patient 
Information Sheet (PIS), in lieu of a consent (Appendix F).  The goal of a PIS is to provide 
sufficient information for possible participants to make a decision or decline study 
participation.101   The University of Kansas Medical Center Human Subjects Committee 
approved this study. 
Focus groups and interviews 
  Focus group participants were identified from non-participant critical observation of the 
paths patients follow through the clinic to identify which staff had significant patient interaction, 
allowing for targeted participant recruitment. These initial observations informed the 
development of the focus group and manager moderator guide (Appendix G).  Participants were 
first asked to describe their experiences and feelings about clinical trials to understand the 
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various perspectives and trial involvement.  Next, participants were specifically asked about how 
clinical trials were conducted prior to the acquisition, prompting discussion about the differences 
before, then after the merger. 
  Focus group participants were approached approximately one week prior to the scheduled 
focus group at their location and were given a PIS. Five focus groups consisting of 2 to 6 
individuals, representing personnel from the front desk and radiation clinics, nurses, medical 
technologists and patient schedulers were conducted.  These focus groups were held at each of 
the five community locations in a private meeting room during business hours.  These focus 
groups did not include any managers, providers, or research staff, allowing these participants to 
freely share their experiences.  A separate focus group with the research staff was held in a 
centralized location to mitigate any influence of being at any one specific clinic.  Each of these 
six sessions lasted about an hour, was audio recorded, then transcribed verbatim.   
  Managers were solicited for semi-structured interview participation and were given a PIS 
to review.  These three semi-structured interviews were held at each manager’s own clinic, in a 
meeting room, which allowed for privacy and confidentiality.  The three managers were asked 
the same questions as the focus groups participants.  Interviews lasted about 30 minutes, were 
audio recorded, then transcribed verbatim.    
  Data from the focus groups and manager interviews informed the development of the 
provider interview guide (Appendix H).   Providers at each of these community cancer centers 
included physicians and nurse practitioners.  Providers were asked about their experiences with 
clinical trials, if they used any clinical trial reminder tools, and if so, which ones and how they 
were used.  Providers were further probed about when participation in a clinical trial was 
presented in the treatment discussion with patients, and how they identified possible trial 
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patients. Finally, providers were encouraged to describe their thoughts and experiences 
specifically related to patient enrollment, both prior to and after the acquisition.  
  Providers were approached to participate in semi-structured interviews, using a brief 
questionnaire with a mix of open and closed-questions to minimize participant burden.  The 27 
interviews were scheduled individually at the providers’ convenience to ensure privacy and 
anonymity.  Each interview lasted approximately 30 minutes.  The provider data were qualitative 
and quantitative in nature, and collected during the interview.   
  Both interview guides included questions about the processes for identifying possible 
trial patients before and after the acquisition.  All participants were asked about their knowledge 
of clinical trials, including any decision support tools that were used.  Providers were asked 
about expected yearly recruitment expectations as well as any concerns with referring patients to 
other health system locations for clinical trial participation.  All data collected were evaluated 
collectively to better understand behavior changes related to opportunity and awareness that 
affected trial enrollment.   
Analysis 
  Data analysis was grounded in the TDF and COM-B frameworks to provide a theoretical 
perspective on the barriers and facilitators that influence behavior associated with clinical trial 
enrollment.  Transcripts from the focus groups,  interviews, and responses from the provider 
interviews, were imported into qualitative analysis software (NVivo102) after anonymization.  
Analysis was conducted using template analysis,103 which uses a codebook to search for pre-
defined themes while allowing flexibility to examine emergent themes.  The codebook 
(Appendix I) was derived from the TDF and COM-B with definitions to identify barriers and 
facilitators104 to clinical trial enrollment.  Special attention was paid to data that did not fit into 
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the existing codes, which mostly represented perceived patient experiences.  References to 
patients were not included since this study focused on organization and physician factors. The 
process for coding each transcript was iterative.  The data were first read, then re-read and coded 
to a draft codebook.  The data were once again reviewed, coding changes made, and the 
codebook revised.  The documents were coded a second time using the final revised codebook.  
As a measure of interrater coding reliability,105 the kappa statistic was run using NVivo. There 
was at least 90% agreement across each coding comparison. Subthemes were identified.  For 
ease of reading, edited verbatim participant quotes are listed in the data tables describing 
experiences after the acquisition.  Data from the closed ended questions were analyzed using 
descriptive statistics.  
  Synthesized member-checking, an in-depth method of member-checking developed by 
Birt and colleagues,106 was used to confirm the results (Appendix J).  A targeted subsample of 
five participants from the original data collection project, directly involved with clinical trial 
conduct before and after the acquisition, were included in this check: 2 physicians, 2 research 
staff, and 1 manager.  For this additional analysis, members were contacted about their 
willingness to participate in an additional interview about the results section of this paper.  
Participants were given at least two days to review the results before scheduling the interview.  
Only one physician agreed to participate.  Final interviews were recorded, then transcribed 
verbatim.  Responses from the four member-checking participants are noted in the results and 
discussion section. 
Results 
Figure 4 shows the enrollment trend of participating community sites in the eleven-year 
span pre- and post-acquisition.  The sites consistently ranked high with patient enrollment across 
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the network with which they were affiliated; enrolling as many as 158 patients in one year to 
both network and pharmaceutical company sponsored trials.  Enrollment drastically dropped 
(70%) surrounding the acquisition (Figure 4).   
 
Figure 4 Community Site Enrollment 2006-2017 
 
Focus groups and interviews 
   A total of 26 individuals participated in one of six focus groups, representing various 
support roles needed for successful trial enrollment. Half (50%) of the managers solicited for 
semi-structured interviews participated (Table 2). As shown in Table 2, of the 35 providers 
approached to participate in additional semi-structured interviews, 27 agreed (77% participation 




































Table 2 Focus Group and Manager Interview Participants 
 Participants  






Role Number of Participants 
Front Desk 
 3  
 
Infusion Nurse 
 3  
 
Medical Technologist 
 3  
 











 5  2 
Triage Nurse 
 3  
 
Manager  3 1 
Nurse Practitioner  6  
Physician  21 1 
Total Participants (56) 26 30 4 
 
Providers 
  Most provider participants were medical oncologists (n=18, 66.7%), followed by nurse 
practitioners (n=6, 22.2%), then radiation oncologists (n=3, 11.1%). There were slightly more 
male than female participants, their ages spanning from the 30s through the 60s, and were evenly 
distributed among years of clinical trial experience (Table 3).    
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Table 3 Demographic Characteristics of Providers Interviewed 
 
*Totals may not total 100% due to rounding. 
  In total, 56 community cancer clinic staff participated in this project (the 4 member-
checking individuals had previously participated). We believed data saturation was achieved, 
meaning similar statements were made repeatedly across and within each group of 
participants,107 and is the criterion for sample size adequacy in qualitative research.108 The 
demonstrative quotes from all types of participants are included in the tables below.   
     
  
Characteristics Number (%) 
27 (100) 
Gender  
Female 12 (44) 
Male 15 (56) 
Age in Years  
<45 8 (30) 
46-55 11 (41) 















<20 14 (52) 
>20 13 (48) 
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 Potential Determinants Associated with Declines in Enrollment into Clinical Trials 
  The community cancer clinic personnel were among the top enrollers to clinical trials 
prior to the acquisition.  In their various roles supporting the conduct of the trials during that 
time, their ability to follow the rigorous trial process was proven successful.  These staff had the 
knowledge and skills required to conduct clinical trials.  Contributing to that success was having 
the opportunity to participate in trials and having appropriate support staff to do so. These staff 
were motivated to conduct clinical trials, as evidenced by several of the member-checking 
participants recalling the competitive fun they experienced each year when the sites challenged 
each other for the most patients enrolled.  All member-checking participants were aware of the 
financial incentives that were awarded if physicians met their yearly enrollment goals, but none 
of them felt this bonus had much influence on enrollment.  These participants described various 
aspects of capability, opportunity, and motivation influencing their ability to enroll patients into 
clinical trials after the acquisition.  Most often, it was opportunity determinants identified from 
across all TDF domains that had the most influence.   
Opportunity 
  The two domains linked to Opportunity are Environmental Context and Resources and 
Social Influences. Both domains were perceived as important in influencing community site 
personnel behavior related to clinical trial enrollment (Table 4).  Specifically, within the domain 
of Environmental Context and Resources, participants expressed frustration related to the dearth 
of clinical trials available to them after having a rich and constant pipeline of studies from the 
former network affiliation.  This scarcity of trials was suggested as one of the biggest barriers by 
nearly all the participants, not only the providers.  Many participants, but especially the 
physicians, mentioned not having staff in the clinic as a significant barrier to enrollment.  One of 
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the managers was exasperated when describing the downsizing of the research staff, which was 
perceived to be a result of not meeting their role expectations, but these expectations could not 
be accomplished without having trials on which to work.   
  Shortly following the acquisition, the community sites were added to the institution’s 
electronic health record system. This affected not only the community sites, but the entire 
network, as everyone was learning how to use the new technology.  For the community sites, 
moving from using hardcopy patient charts and their former network’s database was reported to 
be especially challenging.  Participants also shared concerns about specific actions and inactions 
they felt directly hindered trial enrollment efforts.  For example, not having trials available 
(inaction), nor the support to conduct (action) the trials led to decreased enrollment.   
 Regarding Social Influences, the perceived distinction between the main center versus the 
community sites was another point of frustration, and was a negative social influence.  The 
community staff were told they were part of the overall organization, yet this messaging was not 
consistent in the material presented to the public.  The community staff mentioned the 
inconsistent referral patterns between the various locations.  They felt they were expected to send 
their patients to the main campus for trials, yet the number of patients being referred to them was 
minimal.  When patients called into the main organization’s number, the community staff 
perceived these patients were only being scheduled with oncologists at the main site and not at 
the community sites.   This concerned them, not only for the lack of new patients being 




Table 4 Community Staff Experiences Related to Trial Enrollment After the Acquisition with Sample 
Quotes-Opportunity  







• “When we merged, it was kind of like a dead halt.  
We've had to jump through a lot of hoops to get started 
[again with clinical trials], it seems like.” -cs 
• "It's kind of hard to put somebody on a study when you 
don't have one available." -cs 
• "All the trials we've had out here in the past, we aren't 
getting out here." -cs 
 Research staff • "One of the more immediate challenges right now, we 
don't have a research nurse here." -cs 
• "You can't grow a research department by cutting staff.  
What message does it send to the organization as far as 
the importance of research?  I think it sends very mixed 
messages and it makes you wonder whether the 
organization truly backs the research effort." -m 
 Electronic health 
record 
• "When we went live with Epic, we found out our 
clinical trial research staff was not trained at all on Epic.  
They were doing everything on paper which then 
created a, a different workflow, one that we were trying 
to get away from..." -m 
•  “A hardship for this year for accruals has been the roll-
out of the electronic medical record.  That’s been 
challenging for everyone…with the rollout of the 
electronic medical record, we took a nosedive on 









• "If a patient listens to the media ads, it seems like [the 
main center] is the only location.  The ads need to be 
more inclusive." -p 
• "In the [patient] booklets, [the main center] has a large 
star.  The community sites have smaller icons.  What 
does this say to the patient?  Academic vs. Community--
if the goal is full integration, continuing this distinction 
will make it difficult." -p 
 Referrals • “Patients are adamant about seeing specific doctors 
because the referring physicians told them who to see.” -
cs 
• “You all treated my mother and this was her doctor and 
I want to see him too.” -cs 
• “…had one patient refuse to go to [the main cancer 
center] for a trial.” -p 




  Within motivation, the domain Social/Professional Role and Identity was most prevalent 
(Table 5).    Consistent with focus group and manager responses, nearly all providers (96%, 
n=26) stated that the physician was the primary individual responsible for identifying trial 
patients.  Physicians saw trial enrollment as one of their professional responsibilities, yet to be 
successful, the physicians often mentioned the need to have staff, especially research staff, 
nearby to assist with enrollment activities.  Physicians relied on the research staff to assist in 
study specific procedures and requirements.  The research staff were also seen as resources for 
other clinical personnel and patients for obtaining information about clinical trials. Clinic staff, 
such as nurses, were mentioned by the physicians as needing to take on a more active role in 
identifying patients for study participation, “like the main cancer center nurses”.  This is opposite 
of what nurse practitioners felt their role in trial conduct should encompass. 
 Beliefs about Consequences as another domain within Motivation, was identified in 
responses related to beliefs about the value of clinical trials.  One hundred percent of the 
providers (n=27) agreed that clinical trials were good for the practice and good for patients. 
Many of the focus group participants also discussed perceiving clinical trials being beneficial to 





Table 5 Community Staff Experiences Related to Trial Enrollment After the Acquisition with Sample 
Quotes-Motivation 
TDF Domains Relevant Themes Illustrative Quotes 
Social/Professional 






• "It's really physician driven that has really been 
the greatest success for identifying and moving 
forward with patients." -cs 
• “The most successful approach for getting 
patients on trials comes from the physician due 
to the hope and trust the patient has.” -p 
• “There’s nothing NPs can do to get patients on 
trial.” -p 
 Physicians want 
staff to be active 
in trial recruitment 
• "I would like a full-time research person with 
me to assist with study conduct.” -p 
• “People at [the main academic cancer center] 
have shadows [clinical nurse coordinators].  
This would be the ideal person to identify the 
patient whose treatments are changing or have 
relapsed because they look at the scans.  
Research Study Coordinators won’t have this 
information.” -p 
• “Current road block is that doc doesn't have 
time to go through the patient records, so if [the 
research study coordinator] could determine 
eligibility before the patient visit, that would be 
helpful.”  -p 
 Research staff •  “The research nurse is really the key point…a 
person who would be very helpful on many 
levels.  Not only for the patient but as a 
resource for [staff] and physicians." -cs 
•  “Our physicians are real good about 
[presenting the trial to the patient] what the 
doctor actually knows or feels comfortable 
with explaining and then they hand it over to 
the coordinator to finish.” -cs 
Beliefs about 
Consequences 
Value of trials • "I think that they (trials) are very beneficial." -
cs 




  The community clinic staff discussed having difficulty enrolling patients related to 
Knowledge; Memory, Attention and Decision Processes; and Behavioral Regulation. There were 
few comments about Skills, likely because the skills needed for patient identification and 
enrollment did not change because of this event, so this domain was not included in this review. 
  Knowledge emerged as a prevalent domain, with the identification of themes directly 
related lack of awareness of trials and knowledge of patients’ trial status after the acquisition 
(Table 6).   Twenty-five providers (93%) reported being aware of the available trials by using 
various clinical trial reminder tools.  Non-physician personnel felt like the physicians were more 
aware of available studies prior to the acquisition and suggested the lack of awareness was due to 
not having research staff in clinic as they did before.  Support staff discussed not knowing about 
the trial details, while the nurses were bothered by not knowing which patients were on trial, 
related to the patient’s safety with an investigational medication. 
  Themes related to Memory, Attention and Decision Processes emerged, particularly 
related to using clinical trial tools and differences in workflows.  Most providers and many staff 
discussed frequently using the clinical trial tools to know what studies were available after the 
merger.  Others mentioned the difficulties of using the new tools due to their complexity and 
length. Comments from the radiation oncologists specifically requested to have the tools 
available on the desktops, including for the nurses with whom they worked. Although patients 
were prescreened for trial participation prior to and after the acquisition, the value of 
prescreening was not universally accepted by physicians and research staff.  This remained true 
with the comments from the member-checking, although one physician suggested that as a 
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group, physicians are not aware of the work and effort required for prescreening patients, nor the 
steps for initiating a study. 
 Behavioral Regulation  
  Prior to the merger, patients on clinical trials were easily identified by orange sleeves 
covering the medical charts.   Many support staff, including clinic nurses, expressed concern 
about not knowing which patients were participating in trials. Several schedulers also conveyed 
being anxious about trial patients no longer being clearly identified as they knew patients on trial 
had to follow strict visit dates and procedure timelines.  
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Table 6 Community Staff Experiences Related to Trial Enrollment After the Acquisition with Sample 
Quotes-Capability 





• "I think with USO, we and the doctors knew more about what was 
out there where I don't see as much of that here now. I don't know 
if it's because we don't have a research nurse or we are not getting 
a list anymore or what is going on." -cs 
• "I am aware we have clinical trials, but I don't know which ones." 
-m 
• "I don't even know what they [research staff] do." -cs 
 Trial information • “…I always have to call research and ask them all of this 
information [about the trial] that I should already have available.” 
-cs 
• “We don’t know the patients, we don’t know what drugs they’re 
on, we don’t know the details.  We don’t know the ins and outs of 
the trial.” -cs 
• “I had no idea it was there.” [referring to clinical trial booklet] -cs 
 Patient trial status • "For me, it would be helpful to know, first of all, that the patient is 









• "The most valuable thing for me personally is the physicians 
always get copy of the clinical trial reference guide, they always 
get a copy of the flowsheets, they are always on their desks."  -cs 
• "If I were trying to help identify patients, condensing the list...I'm 
not going to go through the list as easily if it's 50 pages long." -cs 
 Workflow processes-
opposing views 
• “All offices should have a screener to review patient records to 
identify for trial participation”-p 
• “Prescreening patients is the best way to identify for study 
participation.”-p 
• "I don't think it was successful [screening new patient 
charts]…you have to funnel through 86 pages looking for one 
little thing...patients have not been fully diagnosed...so you don't 
even have a clear path on what clinical trial the patient could 
potentially fit into.”-rs 
Behavioral 
Regulation 
 • “[In the past] the charts [of patients on trial] were orange..now 
there is no way of knowing which patients are on trial…” -cs 
• “It would be great for something to either pop up or something of 
identifier when you’re going to schedule the patient…because if 
they are cancelling or rescheduling you’ve got to be able to talk 
with that coordinator…so [the patient is not] kicked off study for 
being non-compliant. Cause for like right now, we are not taking 
that into account.  When I’m getting calls, we are just treating 
them like any other patient.” -cs 




Using the acquisition of a network of community-based cancer clinics by a large tertiary 
healthcare system as a case study, we sought to understand the reasons for the decline in clinical 
trial enrollment using a validated theoretical framework.  Through focus groups and interviews, 
we explored the capability, opportunity, and motivation of the community-based clinic staff for 
identifying and enrolling patients into clinical trials.  These staff perceived the shortage of 
clinical trial opportunities and the lack of support to conduct clinical trials as the primary barriers 
affecting clinical trial enrollment after the acquisition.  Our working theory was that the change 
in organizational resources, group identity, and organizational commitment were particularly 
salient.  This work supports some but not all the determinants associated with the TDF domains 
of Environmental Context and Resources, Social Influences and Social/Professional Role and 
Identity. Consistent with our a priori belief, the community staff perceived their opportunity and 
motivation for conducting trials decreased primarily due to the lack of clinical trials available at 
their sites, the absence of research staff from the clinic, and the introduction of an electronic 
health record system. Each of these factors contributed to the decrease in clinical trial enrollment 
after the acquisition.   
The process for participating in clinical trials substantially changed for the community 
sites after the acquisition.  The network with which they were previously affiliated operated 
similarly to a for-profit site management organization by providing start-up and ongoing support 
services. They had a centralized start-up process, staff to support the start-up efforts, and a 
standardized method for opening new trials.  Essentially, when these sites received a new clinical 
trial protocol, all required start-up items had been completed, so they could begin recruiting 
patients for enrollment right away. These community cancer sites also contracted directly with 
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pharmaceutical companies to conduct clinical trials.  Without the centralized support, the 
research staff were responsible for completing all start-up activities.  It was reported that even 
with this extra workload, most trials were opened within 3 months and oftentimes within 6 
weeks. 
NCI-designated cancer centers require specific protocol reviews which must take place 
before any trials are launched.  The academic center’s processes were much more involved, and 
the apparent lack of communication and misunderstanding regarding the start-up process caused 
anger and frustration. The multiple review committee requirements did not exist with the 
community sites prior to the acquisition; and the reviews could take 6 months to complete.   
Once the number of trials decreased, the leadership decided to reorganize the community 
research site staff which resulted in a decrease in the number of research personnel.  Without 
adequate numbers of appropriately trained staff, projects could not be initiated nor completed, 
including clinical trials.  The absence of research staff in the community clinics was also 
frequently mentioned as an enrollment barrier. 
The community site staff perceived a lack of opportunity to conducting trials (without 
trials and research staff) and this affected their motivation.  Organizational changes affecting the 
community personnel’s capability, opportunity and motivation stymied their ability to enroll 
patients into clinical trials. The changes affected the staff’s behavior in how they conducted 
clinical trials.  Learning new workflows, the increase in the number of their professional 
colleagues, and discovering how to be a part of a much larger organization, can all be evaluated 
using the TDF to better understand the determinants of their behavior, and therefore target 
interventions aimed at changing the behavior.  
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Scant literature exists related to oncologist behavior according to the TDF and the 
relation to offering clinical trials.  Similar to our findings, one study found physician behaviors 
associated with offering cancer clinical trials influenced by constructs within the TDF domains 
of environmental resources; social influences; knowledge; memory, attention and decision 
processes; social/professional role and identity; and beliefs about consequences.109 Others used 
the TDF to examine the barriers and facilitators to treating patients on an experimental (not 
standard of care) arm of an interventional cancer clinical trial and found determinants of 
behavior across many of the TDF domains,41 including the three key domains of this research. 
Specifically, the TDF has been used in multiple studies to understand variability in 
healthcare provider behavior by exploring barriers and facilitators to implementing evidence-
based behaviors.41,104,110,111  In a study of nurses’ adoption of an electronic medication medicine 
system (EMMS), the TDF domain Environmental Context and Resources emerged as a major 
barrier for using the EMMS, due to computer availability, the computer technology and 
competing demands for taking the computer to each patient.112 Adopting a new computer system 
can affect daily performance of routine duties, as identified in the EMMS study.  Our study 
found a similar outcome with the implementation of an electronic health record.  By not being 
able to identify patients on trial, and some staff not having access to the EHR, this created a 
barrier.  Our results also identified this TDF domain as a significant barrier due to the lack of 
available trials and absence of research staff in the clinic.  Without having the resources, 
specifically studies and research staff, behaviors needed for the successful conduct of clinical 
trials were affected.  Interventions for addressing these environmental influences would be to 
ensure clinical trials were open at the community-based clinics and to ensure appropriate 
research staff were available to support the conduct of the trials.  
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Horppu et al. also used the integrated TDF and COM-B framework to understand 
determinants of physician behavior related to temporary work modifications (TWM), rather than 
clinical trials.  They found physician behavior may be influenced by factors related to having the 
knowledge and skills about how to apply the TWMs (capability).  Behavior may also be 
influenced by having the physical resources to conduct TWMs, and experiencing social pressure 
from stakeholders to appropriately utilize TWMs (opportunity).  These physicians were possibly 
motivated by their own beliefs regarding their capability and the consequences of their actions. 
Having used the TDF for conducting a theory-informed assessment, they were able to suggest 
several interventions to target these determinants to promote appropriate use of TWMs.111  Our 
findings were similar in that the participants in our study also identified barriers in their 
capability (not knowing the study initiation process, or which patients were on trial), and 
opportunity (lack of trial opportunities and lack of research staff in the clinic) for conducting 
clinical trials.   
Studies by Ellis et al. used the TDF to first identify behavioral determinants of rural 
urologists’ offer of, and referral to clinical trials, then developed an intervention aimed at 
increasing patient referrals to cancer centers conducting urological clinical trials.40,109 Similar to 
our findings, urologists offering clinical trials were influenced by the TDF domains: 
environmental resources; social influences; knowledge; memory, attention and decision 
processes; social/professional role and identity; and beliefs about consequences.  These 
researchers developed multiple intervention strategies to address the barriers, implemented the 
strategies, then evaluated the results.  Following a similar path, developing interventions to 
address the obstacles to clinical trial enrollment as identified in this study may include engaging 
personnel from across the health system to: 
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• State the overall organizational goal for conducting clinical trials 
• Develop processes for obtaining and conducting appropriate trials 
• Conduct routine evaluations of the organization’s clinical trial enterprise to 
recognize barriers preventing and facilitators enabling goal attainment 
The results support our theory that changes at the organizational level resulted in 
modifications in site personnel behaviors related to clinical trial conduct.  This is, to our 
knowledge, the first study to identify barriers and facilitators of clinical trial enrollment by 
community cancer clinics after acquisition by a large tertiary healthcare system using a validated 
behavior change framework.  
Given the success in enrolling patients into clinical trials prior to the acquisition, it was 
surprising to observe such a dramatic decline in enrollment. The staff perceived a lack of 
available clinical trials for which to enroll patients as the most important obstacle.  The lack of 
available trials has been regularly mentioned in the literature as a barrier to trial 
enrollment,4,21,90,113,114 with one study finding the primary factor limiting accrual was the small 
number of available trials.115          
Once available, the timing of trials also become relevant.  The staff were frequently 
frustrated by the length of time it took to open trials, once there were trials available for opening 
at the community sites.  One participant described the start- up process when working with the 
former network and explained that once a clinical trial protocol was available on the portal, the 
study was often open in less than two months, and each trial was made available to all sites.  
Sharing the required start up process with the community staff would likely have eased some of 
the frustration they expressed in the length of time it took to open trials. 
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Identifying patients for clinical trial participation and subsequent patient enrollment into 
a trial may be related to the environment and resources (opportunity) to do so.  Without having 
available trials at their sites, participants described not having the ability to enroll patients.  
However larger, environmental trends, rather than the organizational changes, may have 
impacted trial availability. One member-checking participant mentioned having more difficulty 
meeting study enrollment goals due to the move toward precision medicine.  Many study 
protocols now include targeted therapies, meaning patients must have a specific gene mutation to 
participate. This decreases the number of eligible patients, whereas in the past, clinical studies 
included large numbers of patients with a specific disease.  Another suggestion for boosting 
enrollment was for sites to have a trial portfolio to match the characteristics of the patients of 
their community.113 This may also become more difficult with the greater use of precision 
medicine. 
  Successful research sites have the infrastructure to support clinical trial conduct, which 
includes having research personnel and support staff.20,31  The absence of research staff in the 
clinics was frequently mentioned as negatively affecting trial enrollment efforts.  Providers 
especially perceived the lack of research staff to support clinical trial conduct as a major barrier.  
Yet, this appeared to be related to trial availability.  One member-checking participant reiterated 
that the research staff was downsized, justified by the lack of enrollment activity.  In analyzing 
these data, the low enrollment activity appears to be related to the unavailability of trials in 
which to enroll.  It is unknown if this factor was taken under consideration when the decision 
was made to reduce staff.  
  The healthcare system installed the electronic health record at the community sites in late 
2014, not too long after the system had been installed at the main location.  As one respondent 
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mentioned, it was not until they were in the process of enrolling a patient that they discovered the 
research staff had not been trained, nor given access to this new system. Prior to implementing 
significant workflow changes, an understanding of who and how the current workflow was 
followed may mitigate potential roadblocks.116    
  Institutional leadership has a profound effect on the well-being and satisfaction of its 
employees.117  Providing appropriate support from an organizational and clinical leadership 
standpoint supports cultural and system-wide adoption of change.118,119  Opening studies, 
hiring/maintaining staff, and managing technology are organizational responsibilities.89  
Organizational leadership tasked with supporting the conduct of clinical trials should consider 
which and how many trials to open to best serve their patient population.  Steps should be taken 
to ensure trials, more specifically appropriate clinical trials, are made available across the 
organization, adequate staff are provided to support the conduct of these trials, and appropriate 
and timely training of new electronic systems is given.   
  The organization environment, support, and staff significantly influenced the community 
site staff’s ability to enroll patients into clinical trials.  Although the press release announcing the 
completion of the acquisition stated research would remain a main mission of the merged 
organization and that leadership would continue developing evidence-based patient care models, 
it is unknown if, prior to this action, all stakeholders were engaged in the strategy development 
initiative, which is often required for successful organizational change.120 
  While the community personnel’s knowledge about how to conduct clinical trials did not 
change, their awareness of trials and processes for running trials changed because of the 
acquisition.  While participants mentioned using the new clinical trial tools to be aware of the 
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trials, they expressed frustration related to dearth of trials available at their own sites.  This lack 
of opportunity to participate in trials affected their motivation to do so. 
Understanding how behavior is motivated can be used to develop interventions, policies, 
and targeted behavior change techniques.121 Yet implementing interventions derived from theory 
must first be feasible, then be relevant to the location, and must have leadership support.112   
Limitations 
There were several challenges in identifying the perceived reasons for the decline in 
cancer clinical trial enrollment by community-based cancer center personnel after acquisition by 
a large tertiary health system. Participants self-selected to participate, thus introducing a source 
of selection bias. It is possible other themes could have emerged if everyone had participated, 
however there was good representation across support staff roles.  Since the researchers were a 
part of the organization studied, social desirability bias related to the responses should be 
considered.  To address this potential bias, participants were provided the PIS prior to 
participation and anonymity of responses was reiterated before each session. This study focused 
on the experiences of the staff from the acquired sites, no data were collected from the acquiring 
institution to understand the enrollment drop from the institution’s perspective.  Coding data 
using template analysis may take sections of text out of context, possibly resulting in loss of 
meaning, however the use of member-checking sought to minimize this source of error. The TDF 
is typically used to develop interview questions and then to analyze the data, but this was not the 
case for this case study. However, retrospective application of the TDF as a coding framework 
has been used by other researchers who reported gathering richer data by not using the TDF for 
drafting interview guides.111  Finally, transferability beyond the health system evaluated in this 
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case study may only be possible in similar settings, such as in the 70 National Cancer Institute 
designated cancer centers, particularly those with academic and community sites.   
Conclusion 
 When contemplating acquiring an entity which historically provided services at a high 
level, in this case enrollment to cancer clinical trials, an evaluation of what will be needed to 
optimally continue providing such services should be considered. The community-based 
personnel in this study perceived many barriers to enrollment being present after being acquired 
by a large tertiary health system.  This study provided evidence of using the TDF for identifying 




Chapter IV: Recording Patient Assessment for Clinical Trial Participation: A 
Study of Radiation Oncologists Across a Single Healthcare System 
 
Introduction 
Adult cancer clinical trial participation continues to lag behind national targets, 
jeopardizing the timely development of effective treatment options.3-5  Increasing discussions 
with patients about trial participation is crucial to boosting enrollment, given that the majority of 
oncology patients (75%) agree to participate in clinical trials when offered.32 Despite most 
oncologists reporting that patients may benefit from clinical trials,87 studies have shown that 
when trials are available, providers offer a trial as a treatment option less than 20% of the time.30  
Oncologists’ failure  to  offer trials to patients is one major barrier to patient enrollment.31,32  
Many physicians report being unaware of available trials.4,33-35,40  Even physicians who 
are very knowledgeable about clinical trials may have individual attitudes and beliefs about a 
patient’s ability to participate (accurate or not), and consequently not even discuss a trial with the 
patient.122 As cancer care providers, radiation oncologists are an important but understudied 
group.  Along with medical oncologists and surgical oncologists, radiation oncologists practicing 
at academic and community cancer centers play a critical role in trial recruitment.123-125  Studies 
focused specifically on radiation oncologist enrollment patterns suggested provider factors were 
significantly correlated with enrollment.122,123 
Professional organizations and national guidelines including the American Society for 
Radiation Oncology and the National Comprehensive Cancer Network, recommend the best 
management for any patient with cancer is a clinical trial.126,127 Having National Cancer Institute 
designation has been shown to increase adherence to cancer treatment guidelines.128  Though 
critical for meeting standards in healthcare as well as providing higher levels of patient care, 
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implementing treatment guidelines can be difficult, and more so in the community setting.129  
There are several reasons physicians may not adhere to guidelines, including lack of awareness 
and knowledge about the guidelines, and the presence of external barriers (i.e., time constraints, 
lack of resources) preventing adherence.130-132 Healthcare leaders have turned to automation for 
making it easier for physicians to follow practice guidelines by  incorporating decision support 
tools within the electronic health record (EHR).133-135  
Best practice, or “pop-up” alerts, have been integrated within the EHR to remind 
physicians to follow guidelines.  As with alerts for safety and routine care, the EHR can also be 
used to facilitate clinical trial patient recruitment. Integrating within the EHR a treatment 
pathway containing clinical trial treatment regimens can alert physicians to the availability of a 
trial,136,137 and clinical trial alerts (CTAs) within the EHR can potentially improve patient 
recruitment to clinical trials.138  Physicians have reported finding CTAs useful, but alert fatigue 
remains a concern.138,139 
The more alerts a physician is exposed to, the less likely action will be taken.140 This 
desensitization to such messages is known as “alert fatigue.”  Alert fatigue is a phenomenon 
found throughout the literature, yet has not been fully investigated using a qualitative approach.  
Thus the best way to overcome alert fatigue is not yet known.141  
 Informing physicians of available trials at the time a treatment is being ordered may be 
too late since the discussion of treatment options with the patient already took place.  The 
physician needs to have trial information before discussing treatment options with the patient.  
Because physicians are often unaware of available trials142 and too busy providing routine patient 
care to remember to offer trial participation, a reminder about clinical trials should be introduced 
early in the patient-physician interaction.143  
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  One potential mechanism for avoiding alert fatigue and promoting discussions about 
clinical trials, is to embed a field for the physician to record assessment of the patient for trial 
participation into the EHR.  The presence of a data input field serves as a reminder for providers 
to consider trial participation as a treatment option for each patient.  Information about this 
approach is important since using the standard EHR workflow to prompt providers and facilitate 
patient recruitment was a recognized option in the United States (US) for meeting meaningful 
use standards.144 Adding the field into a current workflow may prove more effective than a pop-
up alert since the physicians are already familiar with the format.  Documenting the assessment 
can show adherence to treatment guidelines, and awareness of the patient’s current treatment 
status.138  In fact, use of a prompt within the EHR for documenting assessment of patients being 
evaluated for palliative care substantially increased adherence to guidelines.56   The addition of 
an embedded field has strong potential for large-scale implementation considering over 80% of 
US hospitals have implemented the use of an EHR.145    
Physician and organizational characteristics have been linked to differences in cancer 
clinical trial enrollment.89 These links can be understood in the context of the (TDF), where 
physician decision are determined by factors in several domains including Environmental context 
and resources, Knowledge and Skills, and Social/professional role and identity.104  Physician 
characteristics such as gender, time in practice, practice location, and volume of patient visits, 
are used in the literature and proxy some of these factors.57,58  Although imperfect, gender is 
likely to capture some differences in Social/professional role and identity, work experience and 
patient volume likely capture some elements of Knowledge and skills, and practice location 
likely captures elements of Environmental context and resources.  These provider characteristics 
are easily available to health systems at low cost.  Links between these factors and utilization of 
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an EHR field for clinical trial status provide an opportunity to target physician outreach and 
improve trial accrual without incurring the high costs of primary data collection.  The literature 
provides some support for a link between these measures and physician adherence to guidelines, 
with time in practice and academic practice settings generally linked to higher trial 
enrollment,24,25,122,124 and mixed results for gender and guideline adherence, treatment decisions, 
and patient outcomes.57,58,146  The extent to which radiation oncologist characteristics are linked 
to use of an EHR field for clinical trial status is an open empirical question.  
The main contribution of this analysis is to build upon the previous literature by assessing 
which radiation oncologist characteristics are linked to the likelihood that the patient assessment 
field is completed, which serves as a proxy for care consistent with treatment guidelines.  To 
address the importance of provider characteristics, it is necessary to acknowledge the importance 
of patient characteristics in the analysis.  Women have historically been underrepresented in 
clinical trials not focused specifically on women’s cancers.147 The elderly have also been poorly 
represented in trials,148 and patient age has been associated with physicians following 
recommended guidelines.149 Patients with a support system are more likely to enroll into a trial 
than those without.88,150   The type of insurance a cancer patient has affects clinical trial 
enrollment,3,5,114 as well as to what extent treatment guidelines are followed.151  As such, only 
patients with insurance are included in this evaluation.  Because both provider and patient 
characteristics have been correlated with clinical trial enrollment and clinical guideline 
adherence, patient characteristics are included as controls in this analysis. 
To our knowledge, no other study has evaluated radiation oncologist characteristics 
which may predict completion of the EHR field for recording patient clinical trial assessment.  
Radiation oncologists from one health system treating patients at both academic and community 
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cancer centers were included in this study. These oncologists were targeted due to using the same 
EHR, following identical treatment regimens, and treating a wide variety of cancers 
(Environmental context and resources). While the reasons physicians fail to follow treatment 
guidelines, including offering participation in clinical trials are generally known, few studies 
have focused specifically on radiation oncologists and the use of an embedded field within the 
EHR for documenting patient trial assessment.      
Objective 
The aims of this study were to identify key characteristics associated with radiation 
oncologists (i.e., physician characteristics) related to completion of the patient assessment for 
trial participation field in the electronic health record, and to estimate the level of congruency 
between the recorded assessment and the patient’s actual trial status (i.e., physician awareness). 
 
Methods and Materials 
  We conducted a retrospective analysis to examine radiation oncologist characteristics related 
to completion of a field within the EHR for documenting patient assessment for possible trial 
participation. Our study was conducted across a single health system where nearly 100 cancer 
center providers saw over twelve thousand patients each month. The Department of Radiation 
Oncology served five clinics and treated a wide variety of cancers through approximately 15 
radiation oncologists. One radiation oncology clinic was located on the health system’s main 
campus, while the others were stand-alone locations within communities surrounding the main 
campus.  Distance from the main campus location to any of the community clinics was no more 
than 21 miles, while distance between each of the community clinics was approximately 30 





 Data for this study were extracted from automated monthly reports available from the health 
system. These monthly generated reports include data extracted from the EHR and the clinical 
trial management system (CTMS).  The Progress Note template within this healthcare system’s 
EHR was modified to add a field for recording evaluation of the patient for possible trial 
participation at the time of the patient visit. The purpose of adding this field was to remind all 
cancer center providers to consider clinical trials as a treatment option for every patient and to 
document the assessment outcome.  The Progress Note template was identified as the optimal 
location for the addition of this field due to other required patient evaluations already existing in 
this location (i.e., assessing pain and the patient’s ability to perform self-care).  During this 
project, it was discovered that this added field was not a field that required completion (i.e., it 
was not a hard-stop).  EHR fields with hard-stops will not allow the user to proceed without 
entering a response.152  The standardized patient assessment response options available to the 
oncologist are provided as a drop-down menu and include: 
1 Patient currently enrolled in a treatment trial. 
2 Patient currently in screening for a treatment clinical trial. 
3 Patient not eligible for a treatment trial (including not needing treatment, needs palliative care, in remission). 
4 No treatment clinical trial available for this patient. 
5 Discussed clinical trial evaluation with patient and patient declines. 
 
The responses from this field, the patient characteristics (i.e., gender, marital status, type of 
insurance, cancer type, and age), and radiation oncologist practice location, were collected from 
the EHR. Radiation oncologist personal characteristics, such as gender and time in practice were 
obtained from the organization’s website featuring staff from the radiation oncology 
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department.153  A few of the website biographies did not include the date of medical school 
graduation, so the internet was used to search the respective university websites for these dates. 
The CTMS database includes patients who have consented to participate in a clinical trial 
and patients who have been enrolled into a clinical trial.   The CTMS data included in the 
monthly reports reflects patient trial status, such as whether a patient is screening for 
participation or enrolled in a clinical trial.  Examining data from February 2017 through January 
2018 allowed for refinements of the monthly report from its inception in 2014, including the 
addition of patient demographic information included as of February 2017.  
Cohort Definition 
 Visits to radiation oncology clinics providing continuous service from February 2017 
through January 2018 were included in this evaluation.  A total of 78,982 patient visits were 
made to radiation oncology clinics throughout this timeframe1F2.  The goal of this study was 
focused on radiation oncologists treating insured adult cancer patients, therefore patients who did 
not have a cancer diagnosis according to ICD-10-CM classification (Appendix K), were seen by 
a healthcare professional other than a radiation oncologist, who were younger than 21 years old, 
and without insurance were excluded.  The frequency for receiving radiation can vary per 
patient2F3.154   As such, there were multiple visits by the same patient during this timeframe, so the 
first documented visit with a radiation oncologist (index visit) for each patient was evaluated.  
Subsequent patient visits were excluded. One radiation oncologist never entered a response into 
this field, so these data were excluded.  There were 3,729 unique patients included in the final 
analysis.  
                                                 
2 Radiation treatment is given for reasons other than cancer treatment. 




The dependent variable was the completion of the patient assessment field (no/yes). The 
variables of interest were selected based upon the literature on organization, physician, and 
patient characteristics significantly related to guideline adherence and successful clinical trial 
enrollment.  Characteristics from the EHR include clinic location (academic or community), 
patient visit dates (identification of index visit and allowing for calculation of clinic volume), 
and patient characteristics (gender, marital status, type of insurance, cancer diagnosis, and age).  
Patient trial assessment field completion also came from the EHR.  Gender was evaluated as a 
binary variable.  Marital status was analyzed as a dichotomous variable-married (married, life 
partner) and not married (divorced, separated, single, unknown, widowed) since having a support 
system has been associated with trial participation.88   Insurance coverage type was analyzed as a 
dichotomous variable-government (Medicare, Medicare Replacement, Tricare, VA) and 
commercial (BCBS, commercial), since type of insurance coverage has been associated with 
clinical trial participation and treatment guideline adherence by physicians.59,146  Patient cancer 
diagnoses were evaluated as breast or non-breast due to breast cancer being the most common 
cancer in the US155 and the most common malignancy treated with radiation therapy in the US.156  
Patient age was evaluated as a continuous variable.  Radiation oncologist characteristics of 
gender (male or female), and clinic location were dichotomous variables. Time in practice 
(experience) was the time since medical school graduation and was evaluated as a continuous 
variable. 
Analysis 
First, we determined how often the patient assessment field was completed among all 
patient visits.  Second, multivariable logistic regression was used to identify radiation oncologist 
62 
 
characteristics associated with any completion of the patient assessment field.  We estimated 
multivariate models building from parsimonious specifications with heteroskedastic errors to 
models with more rigorous controls and error assumptions to understand the practical 
implications of methodological choices.  The first multivariable logistic regression included only 
radiation oncologist characteristics, followed by a model which combined radiation oncologist 
and patient characteristics.   The purpose of this approach was to assess changes in odds ratio 
estimates between the first two models, which would indicate correlations between omitted 
variables and increase concerns of biased estimates of provider characteristics due to omitted 
patient-level variables.   
Next, we included controls for each of the twelve consecutive months of patient visits to 
account for seasonality and allow for time trends.  The fourth model excludes time controls, and 
adds standard error clustering at the provider level.  In the final model, we included controls for 
visit month and clustered standard error at the treatment (provider) level to understand the 
combined effects of these specific changes.  Results are presented as odds ratios and p-values 
were calculated using Wald Chi-square. P-values of <0.05 were considered statistically 
significant. The Akaike information criterion (AIC) is reported for all models to assess 
differences in model fit. 
To correct for heteroskedasticity, robust standard errors (Huber-White) were used in all 
models.  Because the EHR does not identify the patient’s first visit to the radiation oncology 
clinic, robustness checks were run by first excluding the first two months of this evaluation 
period (8.4 weeks during February and March 2017).  The first three months were also excluded 
(February through April 2017) to fully account for the additional fraction of a week that could 
comprise the maximum oncology treatment timeframe (9 weeks) (Appendix L).  This was to 
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ensure that only the first radiation oncologist visits were captured as any treatment begun before 
February 2017 would likely have been completed by April 2017. 
The assessment of congruency between the radiation oncologist’s recorded response and 
patient actual trial status was determined using Pearson Chi-square analysis.  P-values of <0.05 
were considered to indicate a statistically significant difference. Analyses were carried out using 
Stata version 14.70  
Results 
 One community clinic discontinued offering radiation services in December 2017.  Thus, our 
analysis included the four remaining community clinics.  
Sample characteristics 
 There were 78,982 patient visits made to these radiation oncology clinics from February 
2017 through January 2018.  The CONSORT diagram (Figure 5) describes the sample and the 




Figure 5 Radiation Oncology (RadOnc) Clinic Visits February 2017-January 2018 
Total number of patient visits to Radiation Oncology 
Clinics from February 2017 through January 2018 
(n=78,982) 
Exclude visits of non-cancer patient ICD10 codes (n=6,087) 
 
Visits remaining (n=72,895) 
 
Exclude visits of patients <21 years old (n=2,345) 
 
Visits remaining (n=70,550) 
 
Exclude non-RadOnc provider visits (n=127) 
 
Visits remaining (n=69,289) 
 
Exclude duplicate patient visits (n=64,952) 
Unique patient visits (n=3,729) 
Exclude visits of non-insured patients (n=1,134) 
 
Visits remaining (n=69,416) 
 
Visits remaining (n=4,337) 
 
Exclude visits by RadOnc who never completed assessment field (n=608) 
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Table 7 displays the patient characteristics.  Of the 3,729 insured patients included in this 
analysis, average age was 63.5 (SD=13.1) years and there were slightly more women (52.2%, 
n=1,946) than men (47.818%, n=1,783).  Most patients were married (65.6%, n=2,409). The 
majority (56.8%, n=2,119) had government insurance and a diagnosis other than breast cancer 
(73.2%, n=2,803). 
Table 7 Patient Characteristics 
Patient Characteristics 
N=3729 No. % 
Gender    
   Male 





Age, mean (SD), y 63.5 (13.1) 
Marital Status    
   Not Married 1320 35.4 
   Married 2409 64.6 
Insurance Type    
   Government  2119 56.8 
   Commercial 1610 43.2 
Cancer Type    
   Non-breast  2803 75.2 
   Breast 926 24.8 
 
Radiation oncologist characteristics 
 Table 8 displays the characteristics of the included radiation oncologists. Female 
radiologists are approximately one-third of the staff (27.3%, n=3).  The time in practice of these 





Table 8 Radiation Oncologist Characteristics 
Radiation Oncologist 
Characteristic No. % 
N=11 
Gender     
   Female 3 27.3 
   Male 8 72.7 
Location     
   Community 5 45.5 
   Academic 6 54.5 
Time in Practice, mean (SD), y 16.1 (9.1) 
Volume3F4, mean (SD), m 33 (12) 
 
Field completion 
 The overall (unadjusted) rate of the field completion for recording assessment of the 
patient for trial participation was 42.5% (n=1,585).  Table 9 provides field completion adjusted 
for radiation oncologist and patient characteristics.  Column 1 includes estimates using only 
radiation oncologist characteristics and indicates no statistically significant correlations. This 
model poorly predicts variation in field completion (0.1%).     
By combining both radiation oncologist and patient characteristics (column 2), radiation 
oncologists who were female, who worked in an academic setting, or had more experience, were 
more likely to enter a response into the patient assessment field.  While these characteristics were 
statistically significant, the AIC essentially remained the same, indicating that combining 
radiation oncologist and patient characteristics made little difference. 
                                                 




Column 3 accounts for the time variation (using month fixed effects), revealing similar 
results with a slightly better model fit than column 2.  Column 4 accounts for multiple 
observations by the same radiation oncologist by clustering standard errors.  Notably, this 
reduced the precision of estimates and previously significant radiation oncologist characteristics 
are no longer statistically significant.   
The final column shows data using stronger controls by combining time effects, and 
provider-clustered standard errors.  These modifications improved the fit of the model as noted 
by a large reduction in the AIC, and showed that none of the radiation oncologist characteristics 




Table 9 Logistic Regression Analysis of Radiation Oncologist and Patient Characteristics Associated with 






and RO Chars 
Combined Chars 
with Time Variation 
Combined Chars with 
RO Clustering 
Comb. Chars w/ Time 
Var. & RO Clustering 
Radiation 
Oncologist (RO) 
     
Male Ref1 Ref Ref Ref Ref 
Female 0.97 (0.69) 1.08 (0.37) 0.96 (0.68) 1.09 (0.63) 0.96 (0.86) 
Community Ref Ref Ref Ref Ref 
Academic 0.97 (0.82) 0.92 (0.52) 0.96 (0.76) 0.92 (0.52) 0.96 (0.80) 





Male  Ref Ref Ref Ref 
Female  1.28** (0.002) 1.40*** (<0.001) 1.28 (0.05) 1.40 (0.06) 
Not Married  Ref Ref Ref Ref 
Married  1.00 (0.97) 1.01 (0.87) 1.00 (0.97) 1.01 (0.89) 
Government 
Insurance 
 Ref Ref Ref Ref 
Commercial  1.13 (0.15) 1.14 (0.16) 1.13** (0.01) 1.14*** (0.001) 
Non-breast Cancer  Ref Ref Ref Ref 
Breast Cancer  0.66*** (<0.001) 0.59*** (<0.001) 0.66 (0.15) 0.59 (0.12) 
Age at Index Visit  1.00 (0.79) 1.00 (0.34) 1.00 (0.72) 1.00 (0.09) 
Constant 0.70* (0.04) 0.71 (0.26) 0.11*** (<0.001) 0.71 (0.15) 0.11*** (<0.001) 
R2 0.001 0.005 0.115 0.005 0.115 
AIC 5090.16 5079.63 4539.75 5079.63 4519.75 
1Reference category; p-values calculated using Wald Chi-square *p < 0.05, **p < 0.01, ***p < 0.001; Robust standard errors used 
in each model. 
Robustness checks for identifying the first visit with the radiation oncologist was correctly 
captured showed similar results to the above model.  These two different time models can be 
found in Appendix L. 
Congruency 
Radiation oncologists entered a response in the reminder field 42.5% (n=1585) of the 
time.  When answered, radiation oncologists accurately (94.1%) recorded the patient as not being 
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on trial when the patient was not on trial.  However, radiation oncologists identified patients 
already on trial or in the screening process for entering a trial only 42.7% of the time. 
Additionally, when patients were on trial, radiation oncologists incorrectly recorded patients not 
being eligible 5.9% of the time.  Further, radiation oncologists reported patients being screened 
or enrolled in a trial 57.3%, when they were not (Table 10).   
 Table 10 Congruency Between Radiation Oncologist Response and Patient Trial Status at Index Visit 
 Radiation Oncologist Response 
Patient status 
Screening or Enrolled 
on trial 
Not eligible, 
No trial available, 
Patient declined Total 


















Frequency and percentage represent column totals. 
p-value was 0.00 by Pearson Chi-square analysis. 
 
Discussion 
Many cancer treatment guidelines include participation in a clinical trial as a treatment 
option.127,157  Patients have long reported not participating in clinical trials due to not being 
asked.4,124,158,159 Like medical oncologists, radiation oncologists play an important role in patient 
recruitment and enrollment,124,125 but are often unaware or too busy providing routine care to 
remember to offer a trial as a treatment option.4,33-35,40,142 As a reminder for oncologists to assess 
each patient for possible trial participation, a large Midwestern health system added a field to the 
page in the EHR for documenting patient assessment for possible trial participation. This field 
was strategically added to this page since other routine care assessments were recorded here and 
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oncologists were already familiar with the page as part of their documentation workflow.  This is 
the first study assessing radiation oncologists use of a field within the EHR for recording patient 
assessment for possible trial participation. 
Radiation oncologists entered a response into the patient assessment for clinical trial 
participation for just over one-third of their patients (36.6%).  Patients with commercial 
insurance were most likely to have had this assessment field completed.  These finding are 
consistent with other studies which identified patient characteristics, including insurance, are 
significant factors in patient enrollment24,25,122,124 and guideline adherence.149,151   The effect of 
having breast cancer (controlling for patient gender) was significant in the early models, but was 
not significant in the final model that more rigorously accounted for provider effects. 
While the included radiation oncologist characteristics were expected to capture provider-
specific differences related to field completion, none of these characteristics were statistically 
significant predictors of field completion, and these effects explain only 11% of the variance in 
completion of the patient assessment field. We still do not fully understand the underlying 
mechanisms influencing prompt completion.  In fact, there was one radiation oncologist who 
never completed the field. Reasons for this oncologist never entering a response into this field 
are unknown.  It is possible that a work-around within the EHR was developed to not show this 
field at all, therefore the field would display as blank in the reports.  This could occur if the field 
was hidden or removed into one note, and providers are able to copy and paste their notes from 
one page to another, it is possible this field would not show up at all.  
When the field was completed, most were aware of patients not being on trial (94.1%), 
but were less aware of patients who were already enrolled or were in the process of enrolling 
(5.9%).  This may indicate radiation oncologists’ preference for checking the default of no trial 
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available, without fully understanding the patient’s current trial status. Consideration should be 
given to further collaborating with radiation oncologists to better understand the reasons for not 
completing this field at each patient visit.  As an example, interviewing the non-responding 
radiation oncologist about the understanding of using the prompt and the reasons related to never 
recording a response.   
Radiation treatment frequency can vary per patient, so evaluating the first documented 
(index) visit with a radiation oncologist for each patient within this evaluation period was meant 
to minimize bias by standardizing the evaluation time point across all patients.  It was recognized 
that some patients within this cohort may have already been well into their treatment regimen 
and therefore a change in treatment would not be applicable.  To minimize this potential bias, 
additional analyses were run excluding several months at the beginning of this evaluation period 
to better capture index visits. The results were similar across the three models; therefore, the 
entire study evaluation period is presented. Irrespective of a patient’s index visit, this field could 
have been completed by the oncologist noting that the patient was already on trial, patient was 
not eligible for a trial, or that a trial was not available, rather than leaving the field empty. 
While these oncologists were acutely aware of a patient not being on trial, they rarely 
recorded a response for patients who were already on trial or were in the screening process for 
entering a trial.  This may represent a lack of awareness of the available clinical trials, or may 
indicate the oncologist not fully knowing a patient was already participating in a trial.  It may 
also be that they knew the patient status but chose not to record a response.  Administrators could 
encourage increased field completion overall by providing training, further education, and 
communication about the field’s importance.  Perhaps more importantly, understanding the 
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circumstances surrounding the reasons the one radiation oncologist never entered a response 
could underpin more meaningful interventions. 
Future studies could further examine completion of this field, perhaps through the 
conduct of focus groups or semi-structured interviews with radiation oncologists across this 
health system.  Using qualitative methods to understand radiation oncologist use of this field 
may provide other areas for targeting efforts for increased field completion, particularly if the 
evaluation is theoretically based.43 The current study design could be expanded for evaluating 
other oncologists across this health system, allowing comparison across different specialists, but 
the reasons for low and inaccurate field completion rates should first be ascertained.   
Limitations 
This study is not without limitations.  As part of the Progress Note in the EHR, the 
patient assessment field is completed at the time of the patient’s visit, whereas patient trial status 
from the CTMS is extracted at the end of each month.  It is possible the calculated congruency 
values could be different if patient trial status were matched at the time of the visit.  It should 
also be noted that documenting the patient assessment for possible study participation in the 
EHR is not a required field, therefore it is possible that while every patient is being evaluated, it 
is not being documented, or may be documented in the note as text rather than in the designated 
field.  Alternately, it is possible that patients may not have been assessed at all. Follow up with 
the one oncologist who never entered a response may reveal additional information about how 
and when this field is completed.  It is unclear what training was given about the correct way to 
complete this field, which may have led to misunderstanding of the response categories, and for 




  Despite being added to the EHR workflow where guideline driven patient assessments 
were already being recorded, radiation oncologists completed the field for documenting 
evaluation of patients for possible trial participation less than half the time. Increasing the 
number of patients who participate in trials is unlikely to occur if physicians do not discuss this 
option with their patients. Increasing the completion rate of this field may help in recognizing the 
need for the patient assessment to be performed, which in turn may increase radiation oncologist 
awareness of available clinical trials and patient trial status.  These findings did not demonstrate 
significant correlation between radiation oncologist characteristics and the completion of the 
patient assessment field.  However, to optimize the completion of this field, further study is 




Chapter V: Conclusion  
 
 The quest to identify more effective and less toxic cancer treatments can only be achieved 
through the conduct of clinical trials. The clinical trial process is complex and is influenced by 
organization and oncologist characteristics, as well as external factors such as health policy. 
Billions of dollars are spent each year by the government and private companies conducting 
cancer clinical research, yet some trials are never completed due to low and slow enrollment of 
patients.  By using three distinct research methods, this dissertation contributes to the literature 
by evaluating organization and oncologist characteristics related to the conduct of cancer clinical 
trials.   
 Through survey responses from cancer research centers across the US (n=252), we 
discovered that despite the ACA’s clinical trial mandate, insurers continued denying health 
insurance coverage for patients seeking treatment through participation in clinical trials. The 
primary reason payers reported to sites for denying patient coverage was that the plan did not 
cover trial participation (n=33; 80.5%).  It was not known if denials were intentional or due to 
lack of knowledge of this mandate, but the process of appealing a denial can be lengthy and 
many patients need to begin treatment sooner rather than later. 
 Although academic sites are known for their research efforts and many are NCI-
designated, these sites reported more denials than community-based clinics.  Sites in states with 
previous laws and agreements covering trial participation experienced similar numbers of 
denials.  Furthermore, sites using a precertification process for confirming patient coverage for 
trial participation were significantly more likely to report experiencing denials (69.3% vs. 41.7%, 
χ2=14.9, p<0.001).  These organizational characteristics, and the environment in which and 
through they are operating, are limiting the opportunity for these centers to even offer trial 
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participation to their patients.  When an insurer is unable to respond promptly to the request to 
confirming patient trial coverage, physicians may develop attitudes or beliefs about a patient’s 
ability to become a trial patient.  Without the ability to conduct trials or enroll patients into trials, 
research sites’ efforts will continue to be stymied.  Research centers should consider reviewing 
any processes related to confirming patient insurance coverage to see if steps can be taken to 
facilitate receiving more timely approvals.  Healthcare policy leaders should work to assess the 
ACA’s effectiveness at the patient level to inform future efforts aimed at mitigating this barrier. 
Mergers and acquisitions occur frequently in the healthcare industry.  The motivation 
behind these events are numerous, but one likely reason for most organizations to undertake such 
an effort is to expand their service offerings.  When the acquired or merged organization is not 
performing as planned, steps need to be taken to identify the cause.  We applied a theoretical 
framework to fill the identified gap in theory-based analysis of cancer clinical trial enrollment 
barriers.  By specifically using the Theoretical Domains Framework and COM-B behavior 
wheel, we evaluated the reasons for a drastic drop in enrollment from previously high enrolling 
sites after being acquired.   
We found that the change in organizational structure was negatively associated with their 
opportunity to enroll patients into trials, and the staff perceived this to be due to a lack of 
available trials (50%, n=24), and lack of staff (40%, n=24) to conduct the trials.  Although the 
physician has the most significant impact on trial enrollment, other staff are needed to perform 
trial procedures, such as taking vital signs, drawing blood, administering medication and 
documenting patient outcomes.  In fact, successful research sites have adequate support staff and 
infrastructure to conduct clinical trials,20,24,160 which these sites apparently had prior to the 
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merger as evidenced by their prior enrollment experience (Environmental context and 
resources).   
These organizational changes also affected the physicians directly responsible for patient 
enrollment, not in their knowledge of how to conduct trials, but in their knowledge in how to 
navigate the “new” process for conducting trials.  These physicians frequently mentioned their 
previous knowledge about which trials were available and how there was a decrease in 
awareness about trials following the merger.   Having identified the determinants of the staff’s 
behavior, targeted interventions, such as education to address the knowledge deficits, and plans 
to maintain human and material resources, can be developed.  
Use of alerts and prompts within the EHR to assist providers in making guideline-based 
decisions is common.  Clinical trial enrollment is required by several accrediting agencies.  
Inserting a field in the EHR for recording patient assessment for trial participation where other 
guideline required assessments are recorded was thought to increase discussions with patients 
about clinical trials, and ultimately increase trial enrollment.   
We assessed which radiation oncologist characteristics were linked to the completion of 
this field and found that neither radiation oncologist characteristics, nor patient characteristics 
included in this study had statistically significantly relationships with this field’s completion.  
Further exploration of additional individual and structural factors could help to explain why less 
than half of the oncologists completed this field. 
The dissertation contributes to the literature in three key ways.  This work was the first 
empirical assessment of the Affordable Care Act’s clinical trial mandate.  Next, this work is the 
first to analyze the motivation of the apparent behavior changes of personnel resulting in a 
decline in trial enrollment after acquisition by a larger entity using a validated behavior change 
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framework.  This last essay contributes early evidence that physician and patient characteristics 
overall do not appear to have statistically significant relationships to field completion for 
recording patient assessment for trial participation. Future studies will continue to assess how 
policy affects cancer care delivery, will use theory-based assessment for targeted behavior 
change interventions, and will evaluate adherence to guidelines, as efforts to remove remaining 
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Appendix A: Relationships Between Factors That Lead to Enrollment in a Clinical Trial 
 
 













Appendix B: Model Pathway of Trial Enrollment Process 
 
 




Appendix C: Theoretical Domains Framework and COM-B 
COM-B 




(An awareness of the existence of 
something) 
Knowledge (including knowledge of 
condition /scientific rationale) 
Procedural knowledge 
Knowledge of task environment 
Skills 









Memory, Attention and Decision Processes 
(The ability to retain information, focus 
selectively on aspects of the environment 










(Anything aimed at managing or changing 






(Those interpersonal processes that can 
cause individuals to change their thoughts, 















Environmental Context and Resources 
(Any circumstance of a person's situation 
or environment that discourages or 
encourages the development of skills and 
abilities, independence, social competence, 




Salient events/ critical incidents 
Person x environment interaction 






Social/Professional Role & Identity 
(A coherent set of behaviors and displayed 
personal qualities of an individual in a 










Beliefs about Capabilities 
(Acceptance of the truth, reality or validity 
about an ability, talent or facility that a 










(The confidence that things will happen for 







Beliefs about Consequences 
(Acceptance of the truth, reality, or validity 











(A conscious decision to perform a 
behavior or resolve to act in a certain way.) 
 
Stability of intentions 
Stages of change model 









(Mental representations of outcomes or 










(Increasing the probability of a response by 
arranging a dependent relationship, or 
contingency, between the response and a 
given stimulus.) 
 









(A complex reaction pattern, involving 
experimental, behavioral, and 
physiological elements, by which the 
individual attempts to deal with a 


























































Appendix F: Participant Information Sheet 
SCRIPT FOR INTRODUCING STUDY TO PARTICIPANTS 
Thank you for your interest in this study, Evaluation of How Clinical Trial Participants Are 
Identified in the Community Setting.  This research study seeks to learn how cancer patients 
being treated at The University of Kansas Cancer Center Community Cancer Practice (CCP) 
sites are identified for clinical trial participation. Participation in this research in optional and 
your participation will in no way impact your performance evaluation or employment at UKCC – 
CCP.  Employees at each of the five CCP sites are participating in this research study.  
Individuals in roles that interact with the patients will be asked to participate. 
If you decide to participate, you may be a part of an interview with the research staff, in a focus 
group with other CCP staff or both. Both interactions will focus on gathering information, but 
are organized and conducted differently.  Your participation for the study may take up to an hour 
for each session. In either setting, you will be asked about your interactions with the patients and 
your familiarity with clinical trials. 
There are no known or anticipated risks associated to participation in this study. All information 
you provide is considered completely confidential; your name will not be included or in any 
other way associated with the data collected in the study. Furthermore, because the interest of 
this study is in the average responses of the entire group of participants, you will not be 
identified individually in any way in any written reports of this research.  While we do not expect 
you to personally benefit from this study today, we hope to learn how to improve the process for 
identifying possible participants for oncology clinical trials. 
You may decline to answer any questions presented during the study if you so wish. Further, you 
may decide to withdraw from this study at any time by advising the researcher, and may do so 
without any penalty. 
If you have any questions about the research, you can contact the study Principal Investigator, 
Christine Daley, PhD, at 913-588-2477. Or, if you have any questions about your rights as a 
research participant, you can contact: 
The University of Kansas Human Subjects Committee 
3901 Rainbow Boulevard, Mailstop #1032 





Appendix G: Focus Group and Manager Interview Guide 
  
1. Clinical Trial Awareness 
a. What do you think of clinical trials? 
i. Helpful/harmful to the patients? 
ii. Helpful/harmful to the practice? 
1. More patients to the clinic 
2. Known for cutting edge treatments 
b. How do you know which trials are available? 
i. Monthly Reference Guide 
ii. Trial Flow Sheets 
iii. Staff meetings 
c. How are you made aware of new trials?  
i. From research staff 
ii. Email announcements 
iii. Staff meetings 
d. What would be helpful to you to remember the trials? 
i. Desktop shortcut to Monthly Reference Guide 
ii. Posters/pamphlets 
2. Patient Identification 
a. How were patients identified when you were part of the US Oncology network? 
i. Newly diagnosed 
ii. Relapsed/Recurred 
b. How are patients identified today? 
i. Newly diagnosed 
ii. Relapsed/Recurred 
c. How could we identify these patients? 
i. Newly diagnosed 
ii. Relapsed/Recurred 
d. What is different in the process now than it was with USO? 
e. Once a patient is enrolled to a trial, what type of communication do you feel is 
important to have available to all providers, including schedulers? 
3. Patient Awareness 
a. Of the patients you have discussed clinical trials with, what is your perception of the 
patient’s knowledge and opinion about clinical trials? 
b. Based upon patient feedback, what are the barriers to agreeing to participation in a 
clinical trial? 
4. Other 
a. Do you have any other thoughts or ideas on how to increase trial enrollment? 




Appendix H: Provider Interview Guide 
1. Clinical Trial Awareness 
a. Clinical trials are good for the practice. T/F 
b. Clinical trials are good for the patient. T/F 
c. I am aware of the clinical trials we offer. T/F 
i. I use the clinical trials flow sheet 
1. On the desktop T/F 
2. As a hard copy  T/F 
3. I don’t use the flow sheet 
ii. I use the clinical trials monthly booklet  
1. On the desktop T/F 
2. As a hard copy T/F 
3. I don’t use the booklet 
iii. I would find it helpful to have a hard copy flow sheet outside of each exam room T/F 
iv. How many trials are available at your site today? ________________ 
d. Patients are informed clinical trials are conducted here. T/F 
i. Patients are informed by: 
1. New patient booklet 
2. Brochures 
3. Posters 
4. Staff (name) discuss clinical trials with patients 
5. Other: ____________________________ 
2. Patient Identification 
a. At what point in the patient interaction do you mention clinical trial as a treatment 
option? 
i. At the first visit 
ii. At a follow up visit 
iii. When the patient relapses or progresses 
iv. Whenever I think about it 
v. Other:__________________________________ 
b. How do you communicate to the staff when you identify a possible trial participant? 
i. Tell the study coordinator 
ii. Tell the MA 
iii. Tell the Triage Nurse 
iv. Tell the Scheduler 
v. I don’t 
vi. Other:_________________ 
c. Who is the driver for identifying possible trial participants? 
i. Physician 
ii. NP 
iii. Study Coordinator 
iv. The patient 
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v. The patient’s family 
vi. Other:____________________ 
d. When reviewing a patient’s records, how do you prefer to identify a patient for trial? 
i. Review the flow sheet 
ii. Review the clinical reference guide 
iii. Review the flow sheet and discuss with research coordinator 
iv. Have the research coordinator contact me if they think a patient qualifies 












xii. Other Heme, specify:___________________- 
3. Study Conduct 
a. Have you experienced any difficult in enrolling patients to clinical trials over the past 3 
years? Y/N 
i. What has made it difficult to enroll: 
1. No eligible patients 
2. Patients unwilling to participate 
3. Lack of clinical research staff 
4. Lack of interest in participating in clinical trials 
5. Lack of available clinical trials for study population 
6. Other:___________________________________ 
b. What would make it easier for you to enroll patients into clinical trials? ________ 
c. What is the expected number of patients to be enrolled by you personally this year?_____ 
d. How many patients have you enrolled?____ 
e. What do you consider to be barriers to your recruitment efforts?_______________ 
f. Have you referred any patients to other locations for clinical trial participation? Y/N 
i. Within KU (specify where:______________) 
ii. Outside of KU (specify where:______________) 
g. Do you have any  reservations in referring patients to WW or the CRC for trial 
participation? Y/N 
i. List:_____________________________________________  
h. I want to participate in clinical research Y/N 




a. Gender M/F 
b. Age:______ 
c. Years in practice:_________ 
d. Years conducting clinical research:__________ 
5. If there is one thing you could change today to increase your trial enrollment, what 
would it be and how would you accomplish 
it?_________________________________________________ 




Appendix I: Theoretical Domains Framework and COM-B Codebook 
Notes:  
1. Conceptual framework is the Theoretical Domains and COM-B Framework (Cane et al., 
2012) 
2. Keep in mind the focus is on changes in personnel behavior surrounding the acquisition 
that led to the decline in clinical trial enrollment. 
3. Coding can be domains, using constructs to justify the domain coding.  
4. Make sure to code question as well as response when response does not reflect content of 
question. 
5. Code both affirmative and negative responses. 
6. Code both straightforward identification of issues (e.g., I don’t know what trials are 






Decision Rules Examples 
Capability Knowledge 
 (An awareness of 










Knowledge of task 
environment Participant talks about 
knowledge, or what he/she 
does or does not know. 
Before  
"I think with USO, we and the doctors knew more 
about what was out there where I don't see as much 
of that here now. I don't know if it's because we 
don't have a research nurse or we are not getting a 
list anymore or what is going on." 
 
After 
"I am aware we have clinical trials, but I don't know 
which ones." 
"For me, it would be helpful to know, first of all, 
that the patient is on trial." 
"I don't even know what they [research staff] do." 
"I don't know where else to go to find out what 
studies we're participating in, so I can't direct them 













Expressing personal need 
Describing a skill/action 
"[I need to] become more familiar with the trials." 
 
"You can emphasize that, it’s [participating in a 
clinical trial] going to be a commitment, and you’re 
going to have a little bit of extra stuff to do, but here 
are the benefits and here are the possible benefits.  
You know, you can present it so it’s not terrifying." 
 
"I refer patients to clinicaltrials.gov quite frequently 
because it's just a good source and it assists them 












(The ability to 
retain information, 
focus selectively 
on aspects of the 
environment and 
choose between 









How clinical trial tools are 
being used. 
 
"We need to be made 
aware…" 
Trial reminders 
Workflow is decision 
process, including steps to 
get patient on trial 
Before 
"I don't think it was successful [screening new 
patient charts]... you have to funnel through 86 
pages looking for one little thing...patients have not 
been fully diagnosed...so you don't even have a 
clear path on what clinical trial the patient could 
potentially fit into.." 
 
After 
"If I were trying to help identify patients, 
condensing the list...I'm not going to go through the 
list as easily if it's 50 pages long." 
 
"The most valuable thing for me personally is the 
physicians always get copy of the clinical trial 
reference guide, they always get a copy of the flow 
sheets, they are always on their desks." 
Behavioral 
regulation 













"I've always heard the physicians say that 90% of 
the time, they already have an idea in their mind of 
how they're going to treat that patient before they 
open the door to talk to them." 
 
"What has worked historically [to identify patients 
for trial was] printing out a new list of patients 
coming in...whether it be on a daily basis or weekly 
basis..." 
 
"We used to have charts that instantly told us [it 
was a trial patient].  We have no idea now." 
 
After 
"I don't know that there is any indication [in the 
EMR that the patient is on trial]" 
 
"Not to my knowledge [is a schedule being printed], 
it’s not printed weekly, but I mean they could go in 







Decision Rules Examples 
Opportunity Social influences 
(Those 
interpersonal 
processes that can 
cause individuals 














ACP vs CCP 
 
Mention about anyone 
influencing decision making, 
inc social media 
“Patients are adamant about seeing specific doctors 
because the referring physicians told them who to 
see.”  
 
“You all treated my mother and this was her doctor 
and I want to see him too.” 
 
After 
"In the [patient] booklets, Westwood has a large 
star.  The Community sites have smaller icons.  
What does this say to the patient?  Academic vs. 
Community--if the goal is full integration, 
continuing this distinction will make it difficult." 
 
"If a patient listens to the media ads, it seems like 
[Westwood] is the only location.  The ads need to 
be more inclusive." 
 
"Better integration across CCP and ACP.    More of 
the clinical trials could be done in the community 






























References to staffing 
Trial materials 
Too busy to do trials 
Meetings 
After 
"When we merged, it was kind of like a dead halt.  We've 
had to jump through a lot of hoops to get started, it seems 
like." 
"All the trials we've had out here in the past, we aren't 
getting out here." 
 
"It's kind of hard to put somebody on a study when you 
don't have one available." 
 
"The challenge, I think, in the community is that there's 
no information the majority of the time in O2…there are 
no records in O2 for us to do a pre-screening with 
because they've not been scanned in yet." 
 
“A hardship for this year for accruals has been the roll-
out of the electronic medical record.  That’s been 
challenging for everyone…with the rollout of the 
electronic medical record, we took a nosedive on 
accruals.  We really did." 
 
"When we went live with Epic, we found out our clinical 
trial research staff was not trained at all on Epic.  They 
were doing everything on paper which then created a, a 
different workflow that we were trying to get away 
from..." 
 
"You can't grow a research department by cutting staff.  
What message does it send to the organization as far as 
the importance of research?  I think it sends very mixed 
messages and it makes you wonder whether the 
organization truly backs the research effort." 
 
"One of the more immediate challenges right now, we 











(A coherent set of 
behaviors and 
displayed personal 
qualities of an 
individual in a 














Roles at site 
Research person did/does 
Specific staff for tasks 
Referral patterns 
 
"The other piece as far as identifying patients, 
which is a very difficult one and again goes back to 
keeping research in the forefront of the physician's 
mind, then having available trials and knowing 
what's available when a patient relapses or 
progresses." 
"It's really physician driven that has really been the 
greatest success for identifying and moving forward 
with patients." 
"They’re [research staff] speaking with the 
physicians trying to make sure the physicians know 
which clinical trials are out there." 
“The most successful approach for getting patients 
on trials comes from the physician due to the hope 
and trust the patient has.” 
“There’s nothing NPs can do to get patients on trial.” 
“Current road block is that doc doesn't have time to 
go through the patient records, so if SC could 
determine eligibility before the patient visit, that 
would be helpful.” 
 “The research nurse is really the key point…a 
person who would be very helpful on many levels.  
Not only for the patient but as a resource for [staff] 
and physicians."  
“Our physicians are real good about [presenting the 
trial to the patient] what the doctor actually knows or 
feels comfortable with explaining and then they hand 
it over to the coordinator to finish.” 




(Acceptance of the 
truth, reality or 
validity about an 
ability, talent or 
facility that a person 















With training, more staff 
could help with patient ID 
"I would like to see more information concerning 
what trials are available for what particular cancer 
so I would be able to relay that information to them, 
so they know at least what to attempt to talk to the 
physician about when they have their 
visits...whether it be on the intranet or just put 
somewhere...compiled to say these are the studies to 
better educate us.  Cause we can't help the patient if 
we don't know anything." 
"You'd have to dedicate definitely some staff time, 
a lot of time to track every single new person that 
came in and follow their next two to three visits.  
And what percentage of success would we 
have…statistically not much…which is why I think 
depending on the physicians is probably the most 
efficient way." 
 “More of the trials could be done in the community 







Decision Rules Examples 
Optimism 
(The confidence 
that things will 
happen for the best 
or that desired 






Identity   
" I still think if everyone had to offer the same trials 







(Acceptance of the 
truth, reality, or 
validity about 
outcomes of a 











Lose pt if pt referred for trial 
Acknowledge CT are 
important 
Outcomes of action/inaction 
"I think that they (trials) are very beneficial.” 
 
Before 
"...when we were KCCC, we had a lot more 




"...meeting with [you] has made me more acutely 
aware of the fact that we need to be getting back 
involved with research studies because we've really 
let it go.  We've really let it go..." 
 
"Until the University could adequately provide 
training and oversight to the community group, our 
pipeline was cut.  The new studies being brought on 
it took a while and I don’t think really anyone 
realized how long it was going to take to build the 
department back up after that pipeline was cut.  
Looking at it and saying, you know that’s going to 
take years to get them back to where they were 
because we went almost a year without a new trial." 
 
“[I need] more trials in my DWG (disease group) in 
the community.”   
“[I need] more trials available in the community.”  
Intentions 
(A conscious 
decision to perform a 
behavior or resolve to 
act in a certain way.) 
Stability of intentions 
Stages of change 
model 
Transtheoretical 
model of stages of 
change Motivational factor 
"I've had almost no luck in finding any information 
on patients that are on the schedule for that week 
that are new. I'd like to be able to start the 
conversation of hey, this patient has this diagnosis 
or this information, can you consider this [as a 
possible trial participant] At least I would feel like 
they're benefitting, the physicians, benefitting from 
me being there." 
 












outcomes or end 
states that an 












 Goal is used 
"…having leadership be a part of our management 
meetings….to let us know what the plans are and 
letting us know what our goal is and what we need 

























Methods used to ID trial pts 
Methods to educate people 
about CTs 
Contingency or if-then  
"...depends on someone coming every so often, just 
to like check on things, how things are going 
exactly, making sure everything's going right..."  
 
"…if that message was put out more, this is 
something here [you can do], then KU would be put 
up there with Mayo and MD Anderson…it's like a 
huge surprise to people to hear about KU…you 
guys do that?  I'm saying, if people knew what we 
had there, I think things would be different."  
 
 
"Tell Dr. X to stop yelling at the other docs.  It's not 


















elements, by which 
the individual 
attempts to deal 















"We have good people here--I hope the higher ups 
realize this.  They need to be more supportive 
because we are being blamed for not working 
together and we feel like we have no support." 
 
"None of the docs ever thought research would be 
shut down in the community." 
 
"It's infuriating that it takes so long to open 









Appendix J: Synthesized Member-Checking Questions 
 
 
1. Did you find these comments resonating with the comments you shared during your 
interview/focus group participation? 
 
2. Do you feel like anything is missing? 
 
3. Did anything surprise you? 
 
4. I found it interesting that providers found prescreening helpful but the staff did not.  What 
are your thoughts? 
 
5. Since I conducted these interviews, other stakeholders have mentioned financial bonuses 
being given at the end of the year if enrollment targets were met.  How do you think this 
contributed to the low enrollment? 
 




Appendix K: Non-benign Neoplasm ICD-10-CM Codes 
Neoplasms C00-D49 
Note: 
• Functional activity 
• All neoplasms are classified in this chapter, whether they are functionally active or not.  
An additional code from Chapter 4 may be used, to identify functional activity associated 
with any neoplasm. 
• Morphology (Histology) 
• Chapter 2 classifies neoplasms primarily by site (topography) with broad groupings for 
behavior, malignant, in situ, benign, etc.  The Table of Neoplasms should be used to 
identify the correct topography code.  In a few cases such as for malignant melanoma and 
certain neuroendocrine tumors, the morphology (histologic type) is included in the 
category and codes. 
• Primary malignant neoplasms overlapping site boundaries 
• A primary malignant neoplasm that overlaps two or more contiguous (next to each other) 
sites should be classified to the subcategory/code .8 (‘overlapping lesion’), unless the 
combination is specifically indexed elsewhere.  For multiple neoplasms of the same site 
that are not contiguous, such as tumors in different quadrants of the same breast, codes 
for each site should be assigned. 
• Malignant neoplasm of ectopic tissue 
• Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic 
pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9). 
Codes 
C00-C14  Malignant neoplasms of lip, oral cavity and pharynx 
C15-C26  Malignant neoplasms of digestive organs 
C30-C39  Malignant neoplasms of respiratory and intrathoracic organs 
C40-C41  Malignant neoplasms of bone and articular cartilage 
C43-C44  Melanoma and other malignant neoplasms of skin 
C45-C49  Malignant neoplasms of mesothelial and soft tissue 
C50-C50  Malignant neoplasms of breast 
C51-C58  Malignant neoplasms of female genital organs 
C60-C63  Malignant neoplasms of male genital organs 
C64-C68  Malignant neoplasms of urinary tract 
C69-C72  Malignant neoplasms of eye, brain, and other parts of central nervous system 
C73-C75  Malignant neoplasms of thyroid and other endocrine glands 
C76-C80  Malignant neoplasms of ill-defined, other secondary and unspecified sites 
C7A-C7A  Malignant neuroendocrine tumors 
C7B-C7B  Secondary neuroendocrine tumors 
C81-C96  Malignant neoplasms of lymphoid, hematopoietic and related issues 
D37-D48  Neoplasms of uncertain behavior, polycythemia and myelodysplastic syndromes 
D49-D49  Neoplasms of unspecified behavior 
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Appendix L: Additional Logistic Regression Results 





Combined Pt and 
RO Chars 
Comb. Chars w/ 
Time Variation 
Combined 
Chars with RO 
Clustering 
Comb. Chars 
w/ Time Var. & 
RO Clustering 
Radiation Oncologist (RO)      
Male Ref1 Ref Ref Ref Ref 
Female 0.88 (0.12) 0.98 (0.81) 0.93 (0.53) 0.98 (0.92) 0.93 (0.81) 
Community Ref Ref Ref Ref Ref 
Academic 0.95 (0.70) 0.90 (0.46) 0.94 (0.65) 0.90 (0.56) 0.94 (0.73) 





Male  Ref Ref Ref Ref 
Female  1.48*** (<0.001) 1.54*** (<0.001) 1.48* (0.03) 1.54* (0.04) 
Not Married  Ref Ref Ref Ref 
Married  1.04 (0.64) 1.03 (0.70) 1.04 (0.70) 1.03 (0.76) 
Government Insurance  Ref Ref Ref Ref 
Commercial  1.16 (0.12) 1.17 (0.11) 1.16** (0.01) 1.17** (0.004) 
Non-breast Cancer  Ref Ref Ref Ref 
Breast Cancer  0.58*** (<0.001) 0.56*** (<0.001) 0.58 (0.13) 0.56 (0.12) 
Age at Index Visit  1.00 (0.26) 1.00 (0.27) 1.00 (0.14) 1.00 (0.09) 
Constant 0.99 (0.96) 1.16 (0.66) 0.45** (0.03) 1.16 (0.66) 0.45** (0.04) 
R2 0.002 0.011 0.052 0.011 0.052 
AIC 3862.021 3838.558 3696.542 3838.558 3680.542 
1Reference category; p-values calculated using Wald Chi-square *p < 0.05, **p < 0.01, ***p < 0.001; Robust standard errors used 










and RO Chars 
Combined 






with Time Variation 
and RO Clustering 
Radiation Oncologist (RO)      
Male Ref1 Ref Ref Ref Ref 
Female 0.80 (0.16) 0.86 (0.19) 0.85 (0.15) 0.86 (0.61) 0.85 (0.58) 
Community Ref Ref Ref Ref Ref 
Academic 0.98 (0.88) 0.92 (0.61) 0.94 (0.71) 0.92 (0.68) 0.94 (0.77) 





Male  Ref Ref Ref Ref 
Female  1.53*** (<0.001) 1.57*** (<0.001) 1.53** (0.04) 1.57* (0.04) 
Not Married  Ref Ref Ref Ref 
Married  1.02 (0.81) 1.03 (0.77) 1.02 (0.86) 1.03 (0.83) 
Government Insurance  Ref Ref Ref Ref 
Commercial  1.09 (0.45) 1.10 (0.36) 1.09 (0.14) 1.10 (0.05) 
Non-breast Cancer  Ref Ref Ref Ref 
Breast Cancer  0.61*** (<0.001) 0.58*** (<0.001) 0.61 (0.16) 0.58 (0.13) 
Age at Index Visit  0.99 (0.16) 1.00 (0.21) 0.99 (0.06) 1.00 (0.07) 
Constant 1.13 (0.56) 1.54 (0.25) 0.82 (0.61) 1.54 (0.34) 0.82 (0.70) 
R2 0.003 0.011 0.034 0.011 0.034 
AIC 3280.038 3262.674 3205.535 3262.674 3191.355 
1Reference category; p-values calculated using Wald Chi-square *p < 0.05, **p < 0.01, ***p < 0.001; Robust standard errors used 
in each mode 
